Remedies for pain have progressed beyond the one recommended in Shakespeare’s Romeo and Juliet, where the renowned playwright wrote, “One pain is lessened by another; catch some new infection… and the poison of the old one will die.” Today, a variety of treatment options are available to the sufferer. Alas, many of these come bundled with pernicious side effects and the risk of addiction, making the remedy, in the long term, worse than the ailment. With NeuroRelease™, Cambridge, Massachusetts-based PixarBio Corporation (OTCQX: PXRB) is offering the possibility of release not only from pain but also from dependence on painkillers.
Pain is a ubiquitous phenomenon that pervades our lives from cradle to grave. We bear its lesser manifestations with a grimace or a smile, but, in many instances, analgesics are needed to free us from the greatest torments. For centuries, extracts from opium, derived from the poppy plant, have served that purpose. Perhaps, the most significant of these extracts or alkoloids is morphine, named after Morpheus, the Greek god of dreams.
Morphine, in one form or another, has been used to ease pain since it was isolated from raw opium in 1805. Before that time, a number of preparations, such as laudanum, a solution of opium in alcohol, were employed as painkillers. Morphine is, however, treacherously addictive. Its use during the American Civil War turned large numbers of wounded veterans into addicts. This spurred the search for less addictive analgesics and the employment of weaker opiates such as codeine, which was widely used, at one time, in cough medications.
The quest for less addictive opiates, ironically, led to the discovery of more addictive ones. The German chemist, Felix Hoffman, developed heroin while working in the pharmaceutical research department of what is now Bayer AG. Bayer actually manufactured and sold bottles of heroin medicine in the first decade of the twentieth century (http://dtn.fm/Fw8dD).
In 1909, the U.S. Congress passed the Smoking Opium Exclusion Act, which banned the importation, possession and use of ‘smoking opium’. The statute still allowed for the use of opium-based ‘medications’, however. It was actually the first federal law banning the non-medical use of a substance.
Since that time, a number of FDA-approved drugs have made their appearance, including Vicodin in 1984, OxyContin in 1995 and Percocet in 1999. These are, essentially, all synthetic opiates and, like their natural cousins, are just as addictive. As a result, opioid addiction has mushroomed into a national crisis. The U.S. Department of Health and Human Services (HHS) (http://dtn.fm/2qeUg) has stated that “more people died from drug overdoses in 2014 than in any year on record, and the majority of drug overdose deaths (more than six out of ten) involved an opioid.”
This frightening scenario makes PixarBio’s NeuroRelease™ a welcome addition to the analgesic arsenal. NeuroRelease™ is a morphine replacement, non-addictive pain platform for the surgical and hospital setting, for the battlefield, and for the alleviation of acute and chronic pain in general. The first product FDA approval for the platform is expected to be a 14-day post-surgical pain treatment, and the company anticipates commercial approval for this indication in late 2018.
PixarBio is a specialty pharmaceutical and biotech company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. The company researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Its lead product platform, NeuroRelease™, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models.
For more information, visit www.PixarBio.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, December 27, 2016
Friday, December 23, 2016
At National Waste Management Holdings, Inc. (NWMH), Diverse Revenue Streams lead to Healthy Cash Flow
With close to half a million sitting in the bank and in short-term securities at the end of the third quarter (September 30, 2016), National Waste Management Holdings, Inc. (OTC: NWMH) is flush with cash. This is no happenstance or accident. The company plans to become a vertically integrated behemoth with the long-term goal of servicing the entire East Coast from Florida to New York.
National Waste plans to achieve that vertical integration mainly through acquisitions, a strategy that is already proving to be a huge success. Its revenues for the nine-month period ended September 2016 were $4.9 million, rising by 262 percent over 2015 same period revenues of $1.3 million. Management at National Waste may be forgiven for laughing all the way to the bank. Cash and cash equivalents increased by 31 percent. This is one waste management company that’s wasting no time as it vigorously pursues its objective of becoming a major player in the industry.
A vertically integrated company is one that owns or controls successive stages in the supply chain. Since the end product of one stage would normally be the input to another stage, a vertical integration approach has the potential of streamlining processes and reducing costs. The major oil companies have employed such a strategy with telling effect, with interests in the supply chain from exploration to gas stations.
The waste management business has a similar heterogeneous value chain, composed of landfills, transfer stations, residential dumpster service, commercial dumpster service and residential garbage collection. National Waste, with the complementary strategies of acquisition and vertical integration, has been adding services as quickly as it has been extending its geographic reach.
Two of the driving forces behind National Waste’s winning strategy were interviewed by NetworkNewsWire (NNW), the multifaceted financial news and publishing company. CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor sat down with Stuart Smith to discuss the company’s past milestones and its future goals.
With some 25 years of experience in the solid waste industry under his belt, CEO Louis “Tiny” Paveglio is a bright star in the National Waste firmament. He started as Vice President of Waste Recovery, a position from which he managed day-to-day operations and focused on revenue generation and gross margin profitability.
Under his leadership, Waste Recovery has expanded its roll-offs, built a solid waste transfer station and expanded residential garbage routes. In 2002, Paveglio was made CEO of Sandland, another Teelon company. As CEO, Paveglio made many significant changes to increase productivity and efficiencies.
After some restructuring, he increased profits while the downturn in new construction was hitting the C&D industry. He diversified to keep increasing revenue by trucking recycled materials to other various facilities, saving airspace at the landfill while fulfilling the need for recycled materials. When Sandland was acquired by National Waste, Paveglio assumed the position of CEO.
Dali Kranzthor is CFO of National Waste. As a certified valuation analyst, he is proficient in valuing companies and has assisted clients in this capacity with mergers and acquisitions and tax compliance. Before joining National Waste, he worked for many years at a full service CPA firm as director of audit and assurance and valuation.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
National Waste plans to achieve that vertical integration mainly through acquisitions, a strategy that is already proving to be a huge success. Its revenues for the nine-month period ended September 2016 were $4.9 million, rising by 262 percent over 2015 same period revenues of $1.3 million. Management at National Waste may be forgiven for laughing all the way to the bank. Cash and cash equivalents increased by 31 percent. This is one waste management company that’s wasting no time as it vigorously pursues its objective of becoming a major player in the industry.
A vertically integrated company is one that owns or controls successive stages in the supply chain. Since the end product of one stage would normally be the input to another stage, a vertical integration approach has the potential of streamlining processes and reducing costs. The major oil companies have employed such a strategy with telling effect, with interests in the supply chain from exploration to gas stations.
The waste management business has a similar heterogeneous value chain, composed of landfills, transfer stations, residential dumpster service, commercial dumpster service and residential garbage collection. National Waste, with the complementary strategies of acquisition and vertical integration, has been adding services as quickly as it has been extending its geographic reach.
Two of the driving forces behind National Waste’s winning strategy were interviewed by NetworkNewsWire (NNW), the multifaceted financial news and publishing company. CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor sat down with Stuart Smith to discuss the company’s past milestones and its future goals.
With some 25 years of experience in the solid waste industry under his belt, CEO Louis “Tiny” Paveglio is a bright star in the National Waste firmament. He started as Vice President of Waste Recovery, a position from which he managed day-to-day operations and focused on revenue generation and gross margin profitability.
Under his leadership, Waste Recovery has expanded its roll-offs, built a solid waste transfer station and expanded residential garbage routes. In 2002, Paveglio was made CEO of Sandland, another Teelon company. As CEO, Paveglio made many significant changes to increase productivity and efficiencies.
After some restructuring, he increased profits while the downturn in new construction was hitting the C&D industry. He diversified to keep increasing revenue by trucking recycled materials to other various facilities, saving airspace at the landfill while fulfilling the need for recycled materials. When Sandland was acquired by National Waste, Paveglio assumed the position of CEO.
Dali Kranzthor is CFO of National Waste. As a certified valuation analyst, he is proficient in valuing companies and has assisted clients in this capacity with mergers and acquisitions and tax compliance. Before joining National Waste, he worked for many years at a full service CPA firm as director of audit and assurance and valuation.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, December 21, 2016
Monaker Group, Inc. (MKGI) – Travel Solutions for Every Demographic
Monaker Group (OTCQB: MKGI) is embracing its 65-plus years of operation as a technology-driven travel company to stand out within the leisure travel industries of Europe, Asia, South America and the United States. Using its strategic partnerships, assorted divisions and established travel brands as foundation stones, the company offers travel solutions for various demographics.
As the parent company to leading travel brands, Monaker’s mission is to continue to develop and increase its offerings so as to become the “one stop” vacation center. With its flagship NextTrip brand, Monaker presents discounted travel offerings (airfare, lodging and car rentals, included), and, with its Maupintour brand, it provides its luxury travel products.
Out of a base in South Florida, a committed team of travel and technology specialists leverage Monaker’s high-quality technology platform and strong domain expertise to deliver exceptional service to customers interested in the company’s online marketplaces and sizable inventory of travel products.
Customers who connect with the Maupintour brand get the option of traveling to the best destinations in the world and, by engaging with the brand’s extravagant tours and activities, seeing them from the lap of luxury. Travelers who connect with NextTrip.com, on the other hand, land on a website that unites vital features and functions with sophisticated proprietary and licensed technology in order to present an extensive portfolio of vacation alternatives at cost-effective prices, all under a single platform that gives customers the ultimate power of choice when they book their vacations. The platform is powered by Monaker’s proprietary, groundbreaking booking engine. This engine uses rich content, lush imagery and high-quality video to heighten the site’s customers’ shopping experiences and assist them as they search, decide on and book various vacation products (airlines, hotels, cruises, rental cars, tours and concierge services) and alternative lodging solutions (vacation home rentals, resort residences and unused timeshares).
For more information, visit www.MonakerGroup.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
As the parent company to leading travel brands, Monaker’s mission is to continue to develop and increase its offerings so as to become the “one stop” vacation center. With its flagship NextTrip brand, Monaker presents discounted travel offerings (airfare, lodging and car rentals, included), and, with its Maupintour brand, it provides its luxury travel products.
Out of a base in South Florida, a committed team of travel and technology specialists leverage Monaker’s high-quality technology platform and strong domain expertise to deliver exceptional service to customers interested in the company’s online marketplaces and sizable inventory of travel products.
Customers who connect with the Maupintour brand get the option of traveling to the best destinations in the world and, by engaging with the brand’s extravagant tours and activities, seeing them from the lap of luxury. Travelers who connect with NextTrip.com, on the other hand, land on a website that unites vital features and functions with sophisticated proprietary and licensed technology in order to present an extensive portfolio of vacation alternatives at cost-effective prices, all under a single platform that gives customers the ultimate power of choice when they book their vacations. The platform is powered by Monaker’s proprietary, groundbreaking booking engine. This engine uses rich content, lush imagery and high-quality video to heighten the site’s customers’ shopping experiences and assist them as they search, decide on and book various vacation products (airlines, hotels, cruises, rental cars, tours and concierge services) and alternative lodging solutions (vacation home rentals, resort residences and unused timeshares).
For more information, visit www.MonakerGroup.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, December 20, 2016
Monaker Group, Inc. (MKGI) Issues Update Highlighting 2016 Milestones
Before the opening bell, Monaker Group, Inc. (OTCQB: MKGI), a technology-driven travel company focused primarily on the alternative lodging rental (ALR) market, released a shareholder update outlining its progress throughout 2016, as well as its strategic objectives for the coming year. Some key highlights detailed in this morning’s update include:
- Completion of the company’s proprietary booking engine, which now conforms to all online travel industry standards to allow for easy business to business integration
- Procurement of an extensive collection of rental properties that currently includes over one million lodging options offering ‘real-time’ bookings and more than two million ALR properties
- Anticipated launch of NextTrip.com consumer platform in January 2017 alongside roll-out of business travel partners
- Release of new NextTrip mobile app for both Android and iOS scheduled for the end of January 2017
In addition to a brief overview of the company’s recent progress, this morning’s update included a letter to shareholders from Bill Kerby, chairman and chief executive officer of Monaker Group. After reflecting on the company’s progress during 2016 – including the buildout of its proprietary Monaker Booking Engine (MBE) and ‘plug and play’ application program interface (API), entry into contracts with lodging vendors for roughly two million rental properties and the elimination of over $10 million of debt to effectively strengthen its balance sheet – Kerby turned his attention toward Monaker Group’s future in the rapidly expanding ALR industry, which is on course to reach $169 billion by 2019.
“As the year draws to a close, we can confirm that we expect to launch our alternative lodging rental (ALR) business in January 2017,” Kerby stated in the news release. “This business will have two components. The first is our proprietary Monaker Booking Engine (MBE), which will allow both business travel partners and consumers to access our lodging products. Our other offering, NextTrip.com, is a direct-to-consumer platform that for the first time will provide real-time alternative lodging reservations that include access to all major mainstream travel products and services.”
Kerby and the Monaker Group management team expect both the MBE business solution and the NextTrip consumer platform to be “true game changers in the ALR industry” as a result of their focus on allowing for ‘real-time’ booking. Despite the rising popularity of ALR platforms such as Airbnb, most properties listed through these sites require approval from property owners to confirm bookings. This mechanic has, to this point, limited the integration of ALR listings into popular online travel agencies’ (OTA) service platforms. This issue, combined with a lack of ALR platforms that offer additional mainstream travel services such as flights, rental cars and tour packages, has created a market opportunity that Monaker Group intends to address in the coming months.
“NextTrip will solve both these issues, and, along with our MBE platform, should commence transactional business next month,” Kerby added. “The NextTrip platform has been designed to allow individuals and groups to search, share, converse and recommend vacation destinations, and earn instant “cash back” rewards when they book and contribute to the site… With such rich features, we expect that MBE and NextTrip will appeal to a far greater number of travelers and wholesale travel providers than any other ALR service — and help generate significant booking revenue for Monaker in 2017.”
For more information, visit www.MonakerGroup.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, December 19, 2016
Rennova Health, Inc. (NASDAQ: RNVA) Creating the Next Generation of Health Care
Rennova Health, Inc. (NASDAQ: RNVA, RNVAX), a vertically integrated public holding company serving the health care sector, focuses on offering comprehensive single-source solutions to health care providers ranging from diagnostic laboratory testing to technology solutions, revenue cycle management and financial and billing services. With a declared goal of creating efficient, innovative and empowering solutions, the company is dedicated to putting the needs of health care providers and their patients at the center of everything it does.
The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting better treatment outcomes, increasing patient care efficiency and optimizing revenue streams. Available individually or as a package, these industry-leading supportive software and diagnostics solutions and services work together to empower customers and help shape the next generation of health care.
The diagnostics testing solutions include highly complex clinical, toxicology and esoteric laboratory services, offered via Rennova Health’s subsidiary, Medytox Diagnostics, and its five labs located strategically across the country. These laboratories offer specialized services of urine drug testing for prescription medication, abuse drugs and pain medication, as well as toxicology, clinical chemistry, hematology, serology, immunology and esoteric testing services such as neurotransmitter tests. The testing and sampling process uses the company’s proprietary StableSpot™ methodology.
The company currently has an active customer base with 139 clients and possesses Medicaid licenses in a total of 28 states. Also part of its clinical lab operations segment, Rennova Health recently initiated the acquisition of various assets of a rural clinical access hospital that filed for Chapter 11 bankruptcy. The acquisition process is to be completed early next year, with the hospital and its laboratory likely back in operation in the third quarter of 2017. Another major acquisition the company plans is that of Genomics, Inc., a biomedical diagnostics company that offers personalized medicine via DNA-guided management. Genomics uses a patented combination of genes and a proprietary platform that correlates gene and physiological variability to come up with ideal medication for pain, diabetes, mental illness and heart disease.
Another essential component of Rennova’s comprehensive solutions offering is health care technology. The company’s integrated software solutions include both specialized applications and simplified technologies for electronic health records, an advanced laboratory information management system and a reporting application designed to help streamline diagnostic laboratory testing, as well as information solutions for precision oncology. The company launched an electronic health records service in the substance abuse sector in the last quarter of 2015 and currently has approximately 100 EHR clients across all verticals.
As for revenue cycle management services, Rennova’s in-house medical billing services solution, Medical Billing Choices, offers a customer-centered workflow designed to minimize errors, streamline customers’ billing cycles and maximize cash flow by expediting tasks such as insurance eligibility checks, claims submissions, and payment collecting. The company launched a specialized medical billing division for substance abuse facilities in the third quarter of the year and currently has approximately 20 facilities as customers.
Rennova also offers financial service solutions to health care providers, designed to help them maintain positive cash flows and overcome any income gaps cause by slow-to-pay customers. From special loans collaterized by accounts receivable to acquisitions of qualifying accounts receivable at a discounted rate, the company offers a wealth of financial solutions tailored to every customer.
For 2017 as well as long term, Rennova Health has plans to create and maintain a sustainable relationship with its customers, to grow revenue and provide added value to its shareholders by increasing and diversifying its diagnostics business, offering improved supportive software solutions and exploring new ways to improve provider and patient outcomes for various diagnostics, including cancer and diabetes. The company’s main target markets at the moment are pain management and drug and alcohol rehabilitation.
For more information, visit www.RennovaHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting better treatment outcomes, increasing patient care efficiency and optimizing revenue streams. Available individually or as a package, these industry-leading supportive software and diagnostics solutions and services work together to empower customers and help shape the next generation of health care.
The diagnostics testing solutions include highly complex clinical, toxicology and esoteric laboratory services, offered via Rennova Health’s subsidiary, Medytox Diagnostics, and its five labs located strategically across the country. These laboratories offer specialized services of urine drug testing for prescription medication, abuse drugs and pain medication, as well as toxicology, clinical chemistry, hematology, serology, immunology and esoteric testing services such as neurotransmitter tests. The testing and sampling process uses the company’s proprietary StableSpot™ methodology.
The company currently has an active customer base with 139 clients and possesses Medicaid licenses in a total of 28 states. Also part of its clinical lab operations segment, Rennova Health recently initiated the acquisition of various assets of a rural clinical access hospital that filed for Chapter 11 bankruptcy. The acquisition process is to be completed early next year, with the hospital and its laboratory likely back in operation in the third quarter of 2017. Another major acquisition the company plans is that of Genomics, Inc., a biomedical diagnostics company that offers personalized medicine via DNA-guided management. Genomics uses a patented combination of genes and a proprietary platform that correlates gene and physiological variability to come up with ideal medication for pain, diabetes, mental illness and heart disease.
Another essential component of Rennova’s comprehensive solutions offering is health care technology. The company’s integrated software solutions include both specialized applications and simplified technologies for electronic health records, an advanced laboratory information management system and a reporting application designed to help streamline diagnostic laboratory testing, as well as information solutions for precision oncology. The company launched an electronic health records service in the substance abuse sector in the last quarter of 2015 and currently has approximately 100 EHR clients across all verticals.
As for revenue cycle management services, Rennova’s in-house medical billing services solution, Medical Billing Choices, offers a customer-centered workflow designed to minimize errors, streamline customers’ billing cycles and maximize cash flow by expediting tasks such as insurance eligibility checks, claims submissions, and payment collecting. The company launched a specialized medical billing division for substance abuse facilities in the third quarter of the year and currently has approximately 20 facilities as customers.
Rennova also offers financial service solutions to health care providers, designed to help them maintain positive cash flows and overcome any income gaps cause by slow-to-pay customers. From special loans collaterized by accounts receivable to acquisitions of qualifying accounts receivable at a discounted rate, the company offers a wealth of financial solutions tailored to every customer.
For 2017 as well as long term, Rennova Health has plans to create and maintain a sustainable relationship with its customers, to grow revenue and provide added value to its shareholders by increasing and diversifying its diagnostics business, offering improved supportive software solutions and exploring new ways to improve provider and patient outcomes for various diagnostics, including cancer and diabetes. The company’s main target markets at the moment are pain management and drug and alcohol rehabilitation.
For more information, visit www.RennovaHealth.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, December 16, 2016
National Waste Management Holdings, Inc. (NWMH) Set to Capitalize on Untapped East Coast Opportunities
The increasing levels of solid waste generated in the U.S. each year is drawing attention from lawmakers, and strategies are being implemented on every level to address the issue. The U.S. Department of Agriculture (USDA) is taking steps (http://dtn.fm/tKM4H) to tap into the minds of state and local government entities, academic institutions, and private non-profit organizations by making available Solid Waste Management (SWM) and Technical Assistance and Training (TAT) grants to improve planning and management of solid waste sites in rural areas. In the business sector, National Waste Management Holdings (OTC: NWMH), a solid waste management company, has been steadily expanding its influence across the East Coast with an aggressive acquisition strategy that is bringing more and more facilities under its wing. The company’s comprehensive waste management approach includes an array of landfill disposal services, roll off containers for rental, and a line of recycled wood and garden mulch.
In a recent, exclusive audio interview (http://dtn.fm/7Yj2m) with NetworkNewsWire, a multifaceted financial news and publishing company, National Waste Management Holdings CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor spoke toward a few of the company’s 2017 acquisition goals. A recent article cites a paper shredding facility in New York as being under consideration, and that acquisition would open NWMH to a sizable market in the region. As it stands, NWMH already services residential and commercial customers in Upstate New York, as well as in its home state of Florida.
An article (http://dtn.fm/8tRw2) from the Proceedings of the National Academy of Sciences of the United States of America found, upon examining the world’s megacities, that New York exceeds the rest in solid waste production, both in absolute and per capita terms. In addition, despite Tokyo being the largest megacity by population, New York surpasses it in terms of energy consumption of both transportation fuels and heating/industrial fuels. The article also states that New York consumes the energy of approximately two megacities; the equivalent of approximately one supertanker every 1.5 days. Interestingly, statistics in the 2014 Tables and Figures (http://dtn.fm/iWhx3) published by the EPA last month show that the Northeast more than doubles the rest of the nation in terms of municipal waste-to-energy capacity, with nearly 800 tons/day throughput per million people. Resource recovery facilities can turn solid waste into vital energy. One such facility, for example, is the Essex County Resource Recovery Facility that processed 2,800 tons of municipal solid waste per day in 2012 between its two generators, producing approximately 65 megawatts of energy.
While the Northeast led in terms of waste-to-energy capacity as well as estimated MRF throughput in 2014, it had, by far, the least number of landfills in the U.S., per the EPA report, potentially signifying a largely untapped market. SaveOnEnergy.com notes (http://dtn.fm/IebN2) that New York is the largest giver of trash to Ohio, accounting for nearly 32 percent of the state’s out-of-state total, with New Jersey coming in close behind. National Waste Management Holding’s initial acquisition strategies on the East Coast are part of the company’s larger objective of national expansion.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
In a recent, exclusive audio interview (http://dtn.fm/7Yj2m) with NetworkNewsWire, a multifaceted financial news and publishing company, National Waste Management Holdings CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor spoke toward a few of the company’s 2017 acquisition goals. A recent article cites a paper shredding facility in New York as being under consideration, and that acquisition would open NWMH to a sizable market in the region. As it stands, NWMH already services residential and commercial customers in Upstate New York, as well as in its home state of Florida.
An article (http://dtn.fm/8tRw2) from the Proceedings of the National Academy of Sciences of the United States of America found, upon examining the world’s megacities, that New York exceeds the rest in solid waste production, both in absolute and per capita terms. In addition, despite Tokyo being the largest megacity by population, New York surpasses it in terms of energy consumption of both transportation fuels and heating/industrial fuels. The article also states that New York consumes the energy of approximately two megacities; the equivalent of approximately one supertanker every 1.5 days. Interestingly, statistics in the 2014 Tables and Figures (http://dtn.fm/iWhx3) published by the EPA last month show that the Northeast more than doubles the rest of the nation in terms of municipal waste-to-energy capacity, with nearly 800 tons/day throughput per million people. Resource recovery facilities can turn solid waste into vital energy. One such facility, for example, is the Essex County Resource Recovery Facility that processed 2,800 tons of municipal solid waste per day in 2012 between its two generators, producing approximately 65 megawatts of energy.
While the Northeast led in terms of waste-to-energy capacity as well as estimated MRF throughput in 2014, it had, by far, the least number of landfills in the U.S., per the EPA report, potentially signifying a largely untapped market. SaveOnEnergy.com notes (http://dtn.fm/IebN2) that New York is the largest giver of trash to Ohio, accounting for nearly 32 percent of the state’s out-of-state total, with New Jersey coming in close behind. National Waste Management Holding’s initial acquisition strategies on the East Coast are part of the company’s larger objective of national expansion.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Higher Price Target for Ocera Therapeutics (NASDAQ: OCRX) as Hepatic Encephalopathy Treatment Study Moves Forward
An innovative potential treatment for hepatic encephalopathy created by Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a unique product on an under-served market, and if clinical trials are successful, it could become a major source of success and profitability for the company, according to an Aegis Capital Corp. report (http://dtn.fm/J0h97) released on December 8. The report reiterates a ‘Buy’ rating for Ocera and recommends a higher stock price target of $8, compared to the $2.1 at the time of the analysis.
The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead product candidate OCR-002 – an acute treatment for hepatic encephalopathy and hyperammonemia in patients with acute liver injury, acute liver failure and liver cirrhosis. The phase 2B study, called STOP-HE, will evaluate the safety, efficacy and tolerability of OCR-002 (Ornithine Phenylacetate) in hospitalized patients suffering from hepatic encephalopathy. The study enrolls a total of 230 subjects, which will be administered either OCR-002 or a placebo intravenously for five days. Based on their degree of liver impairment, patients will be given various doses of the drug, ranging from 10 to 20 grams over a 24-hour period.
Top-line data are due in the first quarter of 2017, which Aegis experts expect will be a share inflection point for the company. The study’s primary goal is to archive a meaningful clinical improvement in hepatic encephalopathy symptoms, so as to keep OCR-002 on track to potentially becoming a first-line, foundational therapy of choice for patients with this condition, on a market with significant unmet medical needs. Hepatic encephalopathy is a progressive complication of liver failure of cirrhosis which is marked by partial cognitive impairment including disorientation, confusion and impaired motor skills, while more severe forms can lead to coma and even the patient’s death.
According to the Agis report, there are currently only two hepatic encephalopathy products on the market, with others in development. Lactulose is a first-line therapy that has the largest market share at the moment, while Rifaximin is a second-line therapy. But Aegis analysts believe that OCR-002 has great potential and can take a significant market share, being unique in several respects: it has a unique mechanism of action as an ammonia scavenger, it is the only drug that can be administered intravenously and it has the potential to significantly shorten hospital stays.
If the phase 2B trial is successful, OCR-002 could reach approximately 170,000 patients that have hepatic encephalopathy and require hospitalization. Aegis analysts expect the therapy to achieve at least 22 percent market share and yield revenues of approximately $150 million. Ocera is also developing an oral formulation of the drug for chronic use, with the goal of preventing hepatic encephalopathy recurrences. The oral formulation was not included in the Aegis analysis, but it may indeed help provide an even larger share of the market.
As for potential risks for investors as identified in the report, these include typical manufacturing, commercialization, research and development, and regulatory risks that generally result from investing in pharmaceutical companies. The analysis also points out a series of specific risks of investing into Ocera, such as relying on the success of OCR-002, the company’s liquidity and high volatility.
For more information, visit the company’s website at www.ocerainc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead product candidate OCR-002 – an acute treatment for hepatic encephalopathy and hyperammonemia in patients with acute liver injury, acute liver failure and liver cirrhosis. The phase 2B study, called STOP-HE, will evaluate the safety, efficacy and tolerability of OCR-002 (Ornithine Phenylacetate) in hospitalized patients suffering from hepatic encephalopathy. The study enrolls a total of 230 subjects, which will be administered either OCR-002 or a placebo intravenously for five days. Based on their degree of liver impairment, patients will be given various doses of the drug, ranging from 10 to 20 grams over a 24-hour period.
Top-line data are due in the first quarter of 2017, which Aegis experts expect will be a share inflection point for the company. The study’s primary goal is to archive a meaningful clinical improvement in hepatic encephalopathy symptoms, so as to keep OCR-002 on track to potentially becoming a first-line, foundational therapy of choice for patients with this condition, on a market with significant unmet medical needs. Hepatic encephalopathy is a progressive complication of liver failure of cirrhosis which is marked by partial cognitive impairment including disorientation, confusion and impaired motor skills, while more severe forms can lead to coma and even the patient’s death.
According to the Agis report, there are currently only two hepatic encephalopathy products on the market, with others in development. Lactulose is a first-line therapy that has the largest market share at the moment, while Rifaximin is a second-line therapy. But Aegis analysts believe that OCR-002 has great potential and can take a significant market share, being unique in several respects: it has a unique mechanism of action as an ammonia scavenger, it is the only drug that can be administered intravenously and it has the potential to significantly shorten hospital stays.
If the phase 2B trial is successful, OCR-002 could reach approximately 170,000 patients that have hepatic encephalopathy and require hospitalization. Aegis analysts expect the therapy to achieve at least 22 percent market share and yield revenues of approximately $150 million. Ocera is also developing an oral formulation of the drug for chronic use, with the goal of preventing hepatic encephalopathy recurrences. The oral formulation was not included in the Aegis analysis, but it may indeed help provide an even larger share of the market.
As for potential risks for investors as identified in the report, these include typical manufacturing, commercialization, research and development, and regulatory risks that generally result from investing in pharmaceutical companies. The analysis also points out a series of specific risks of investing into Ocera, such as relying on the success of OCR-002, the company’s liquidity and high volatility.
For more information, visit the company’s website at www.ocerainc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, December 15, 2016
NuVasive, Inc.’s (NASDAQ: NUVA) Speed of Innovation and Absolute Responsiveness form the Backbone of its Rapid Growth
How does a start-up venture capital-backed company grow its revenues to nearly a billion dollars in the global spine industry in less than two decades? By developing a competitive advantage in Speed of Innovation® and Absolute Responsiveness®, two concepts that have made NuVasive, Inc. (NASDAQ: NUVA) the number three company in the spine industry with over 90 products in its portfolio, including lumbar, thoracic, and cervical applications; neuromonitoring services; and biologics solutions.
The global spinal implants and surgical devices market ‘is expected to reach USD 17.27 Billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021’, according to a press release from MarketsandMarkets (http://dtn.fm/uHV0W). Increasing longevity and the resulting larger elderly population means more spinal disorders, such as herniated discs, degenerative disc disease, spondylolisthesis, prolapsed intervertebral discs, and spinal stenosis. In addition, the development of minimally invasive surgical (MIS) procedures is leading to wider adoption of technologically advanced spinal implants.
MIS is NuVasive’s forte. The company is best known for developing the eXtreme Lateral Interbody Fusion® (XLIF) procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of the company’s many innovative procedures, which have redefined spine surgery and opened doors to treat pathologies not previously treated with minimal disruption.
NuVasive has also developed a revolutionary nerve avoidance monitoring system (NVJJB™ /M5®) designed to help ensure nerve and spinal cord safety – this unique and advanced technology may help reduce the incidence of injury to neural elements during spinal procedures by providing real-time feedback and notifying surgeons immediately of any neurological insult. Additionally, NuVasive offers a portfolio of biologics products to help in the bone healing process.
A recent report from Aegis Capital (http://dtn.fm/H1sQC) suggests that NuVasive’s rapid growth is far from over. The company has been steadily paring manufacturing inefficiencies. As a consequence, gross profit has hovered around 75 percent. Other operating margin improvements are expected from economies of scope as the marketing offering expands and economies of scale form an increasingly larger international footprint. Aegis sees “900bp of operating improvements to come, which will continue to drive value.”
In a fast growing industry (2–3% p.a.), NuVasive, focused on developing minimally disruptive surgical products and procedures for the spine, is a fast growing company (2-3x faster than the overall market). The drivers of growth are its ‘expanding platform of offerings, adapting a holistic approach with regards to its sales effort, and increased Integrated Global Alignment (iGA) integration which allows better planning for deformity and saves cost.’
Alignment is one of three important factors to be considered when spine surgery is being contemplated. In cases of spondylolisthesis, for example, the first concern is usually decompression of the nerves to ease any pain or discomfort the patient may be experiencing. In many instances, this means removing the disc or other offending piece from the spine. The resulting space is, typically, filled by bone graft or a synthetic substance in a procedure known as lumbar interbody fusion (LIF). At this point, alignment procedures to straighten the spine may be implemented.
NuVasive, which has a presence in over 30 countries and employs more than 1,600 people globally, had revenues of $811 million in 2015. A 17 percent increase to $953 million is expected this year. Aegis has initiated coverage with a ‘Buy’ rating and a price target of $72.00. The stock, trading on the NASDAQ under the symbol NUVA, is currently around $67.00.
For more information, visit www.nuvasive.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The global spinal implants and surgical devices market ‘is expected to reach USD 17.27 Billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021’, according to a press release from MarketsandMarkets (http://dtn.fm/uHV0W). Increasing longevity and the resulting larger elderly population means more spinal disorders, such as herniated discs, degenerative disc disease, spondylolisthesis, prolapsed intervertebral discs, and spinal stenosis. In addition, the development of minimally invasive surgical (MIS) procedures is leading to wider adoption of technologically advanced spinal implants.
MIS is NuVasive’s forte. The company is best known for developing the eXtreme Lateral Interbody Fusion® (XLIF) procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of the company’s many innovative procedures, which have redefined spine surgery and opened doors to treat pathologies not previously treated with minimal disruption.
NuVasive has also developed a revolutionary nerve avoidance monitoring system (NVJJB™ /M5®) designed to help ensure nerve and spinal cord safety – this unique and advanced technology may help reduce the incidence of injury to neural elements during spinal procedures by providing real-time feedback and notifying surgeons immediately of any neurological insult. Additionally, NuVasive offers a portfolio of biologics products to help in the bone healing process.
A recent report from Aegis Capital (http://dtn.fm/H1sQC) suggests that NuVasive’s rapid growth is far from over. The company has been steadily paring manufacturing inefficiencies. As a consequence, gross profit has hovered around 75 percent. Other operating margin improvements are expected from economies of scope as the marketing offering expands and economies of scale form an increasingly larger international footprint. Aegis sees “900bp of operating improvements to come, which will continue to drive value.”
In a fast growing industry (2–3% p.a.), NuVasive, focused on developing minimally disruptive surgical products and procedures for the spine, is a fast growing company (2-3x faster than the overall market). The drivers of growth are its ‘expanding platform of offerings, adapting a holistic approach with regards to its sales effort, and increased Integrated Global Alignment (iGA) integration which allows better planning for deformity and saves cost.’
Alignment is one of three important factors to be considered when spine surgery is being contemplated. In cases of spondylolisthesis, for example, the first concern is usually decompression of the nerves to ease any pain or discomfort the patient may be experiencing. In many instances, this means removing the disc or other offending piece from the spine. The resulting space is, typically, filled by bone graft or a synthetic substance in a procedure known as lumbar interbody fusion (LIF). At this point, alignment procedures to straighten the spine may be implemented.
NuVasive, which has a presence in over 30 countries and employs more than 1,600 people globally, had revenues of $811 million in 2015. A 17 percent increase to $953 million is expected this year. Aegis has initiated coverage with a ‘Buy’ rating and a price target of $72.00. The stock, trading on the NASDAQ under the symbol NUVA, is currently around $67.00.
For more information, visit www.nuvasive.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Nano Dimension Ltd. (NASDAQ: NNDM) Revolutionizing the Way Electronics are Made with 3D Printing
Nano Dimension Ltd. (NASDAQ: NNDM) is the holding company for Nano Dimension Technology Ltd., a company in the business of researching, developing, and manufacturing three-dimensional (3D) printers for printed circuit boards (PCBs). The company also develops nano ink materials and other products for electronics. NNDM has the vision of revolutionizing the way electronics are made with 3D printing by using 3D printers for multilayer PCBs, along with advanced nanotechnology-based conductive and dielectric inks.
Since the beginning of last year, Nano Dimension has won the Europe 2015 Award for Best Development in 3D Printing Equipment, the Gartner ‘Cool Vendor’ in 3D Printing 2016, and the TÜV SÜD Innovation 2016 award. NNDM is equipped with an experienced managerial team with a long background in the technology and 3D printing spaces, and the company is well-positioned to capitalize on the PCB prototyping industry, which is currently worth approximately $70 billion.
With the launch of its new DragonFly 2020 3D Printer to select beta customers in the U.S., Israel, and Germany, during the third and fourth quarters of this year, Nano Dimension Ltd. is expected to make sales on a more commercial level as early as 2017. The printer, which comes with specialized 3D software as well as conductive and dielectric inks, has now received attention from over 2,500 entities currently on the information waitlist. In addition, more than 30 NDAs have been signed to enable the collaboration and evaluation of this equipment.
With its new printer, Nano Dimension Ltd. plans to provide its clients with more advanced solutions than ever before while tapping into additional markets. Through the DragonFly 2020 3D Printer, Nano Dimension expects to meet the needs of additional market segments by offering faster solutions that print larger objects from a broader materials portfolio with functional inks.
According to The Daily Quint (http://dtn.fm/j5xiP), Nano Dimension has been the topic of conversation for several research analysts firms, receiving a consensus ‘Buy’ rating from five investment analysts with a consensus average price target of $12.60 per share. At close of market on December 13, 2016, the company’s shares were sold at an individual price of $6.05. NNDM’s market capitalization currently stands at $46.96 million.
For more information, visit www.nano-di.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Since the beginning of last year, Nano Dimension has won the Europe 2015 Award for Best Development in 3D Printing Equipment, the Gartner ‘Cool Vendor’ in 3D Printing 2016, and the TÜV SÜD Innovation 2016 award. NNDM is equipped with an experienced managerial team with a long background in the technology and 3D printing spaces, and the company is well-positioned to capitalize on the PCB prototyping industry, which is currently worth approximately $70 billion.
With the launch of its new DragonFly 2020 3D Printer to select beta customers in the U.S., Israel, and Germany, during the third and fourth quarters of this year, Nano Dimension Ltd. is expected to make sales on a more commercial level as early as 2017. The printer, which comes with specialized 3D software as well as conductive and dielectric inks, has now received attention from over 2,500 entities currently on the information waitlist. In addition, more than 30 NDAs have been signed to enable the collaboration and evaluation of this equipment.
With its new printer, Nano Dimension Ltd. plans to provide its clients with more advanced solutions than ever before while tapping into additional markets. Through the DragonFly 2020 3D Printer, Nano Dimension expects to meet the needs of additional market segments by offering faster solutions that print larger objects from a broader materials portfolio with functional inks.
According to The Daily Quint (http://dtn.fm/j5xiP), Nano Dimension has been the topic of conversation for several research analysts firms, receiving a consensus ‘Buy’ rating from five investment analysts with a consensus average price target of $12.60 per share. At close of market on December 13, 2016, the company’s shares were sold at an individual price of $6.05. NNDM’s market capitalization currently stands at $46.96 million.
For more information, visit www.nano-di.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
eXp World Holdings, Inc. (EXPI) Partners with MZ Group to Bolster Investor Relations and Outreach Efforts
Before the opening bell, eXp World Holdings, Inc. (OTCQB: EXPI), the holding company for The Agent-Owned Cloud Brokerage®, announced its retention of MZ Group as its investor relations advisor. Moving forward, MZ Group will assist and advise EXPI regarding its ongoing communications with shareholders with the aim of strengthening the company’s public brand and broadening its investor base.
“We have chosen to partner with MZ Group to bolster our investor relations and outreach efforts during this time of rapid growth within our Company,” Glenn Sanford, founder, CEO and chairman of EXPI, stated in this morning’s news release. “While we have more than doubled in size over the past year due in large part to the dedicated efforts of our existing agent and broker network, we believe there is room for sustained growth as we continue to invest in our core infrastructure and agent and broker network.”
In recent months, EXPI, through the expansion of subsidiary eXp Realty, has recorded strong growth in terms of both market reach and financial results. As of its latest report, the company’s real estate brokerage division had more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. This marks an increase of nearly 155 percent from the beginning of 2016, when eXp Realty reported just 864 agents.
This market growth has translated into strong financial performance for EXPI in 2016, demonstrating the viability of the company’s current growth strategy. Last month, EXPI released its financial results for the third quarter of 2016, which included a 112 percent year-over-year increase in total revenues to $15.7 million. In the update, the company’s management team attributed this increase to eXp Realty’s growing sales agent base and the resulting rise to sales volume being generated by the real estate brokerage division.
EXPI’s share price has been on a similarly-promising upward trend throughout much of 2016. In January, the company’s PPS hovered around $0.84. By October, EXPI’s common stock climbed to a record high of more than $5.80 following the announcement of a new strategic partnership with Commissions, Inc., a leading provider of web-based real estate marketing and CRM software. The company’s stock is currently trading at around $4.35 per share.
News of EXPI’s retention of MZ Group comes just days after the company’s real estate brokerage division was recognized as a winner of the Oklahoma 2016 Top Workplaces Award by The Oklahoman newspaper. eXp Realty has previously received similar recognition in both Washington, D.C. and Atlanta for its commitment to creating a collaborative, engaging and rewarding work environment.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“We have chosen to partner with MZ Group to bolster our investor relations and outreach efforts during this time of rapid growth within our Company,” Glenn Sanford, founder, CEO and chairman of EXPI, stated in this morning’s news release. “While we have more than doubled in size over the past year due in large part to the dedicated efforts of our existing agent and broker network, we believe there is room for sustained growth as we continue to invest in our core infrastructure and agent and broker network.”
In recent months, EXPI, through the expansion of subsidiary eXp Realty, has recorded strong growth in terms of both market reach and financial results. As of its latest report, the company’s real estate brokerage division had more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. This marks an increase of nearly 155 percent from the beginning of 2016, when eXp Realty reported just 864 agents.
This market growth has translated into strong financial performance for EXPI in 2016, demonstrating the viability of the company’s current growth strategy. Last month, EXPI released its financial results for the third quarter of 2016, which included a 112 percent year-over-year increase in total revenues to $15.7 million. In the update, the company’s management team attributed this increase to eXp Realty’s growing sales agent base and the resulting rise to sales volume being generated by the real estate brokerage division.
EXPI’s share price has been on a similarly-promising upward trend throughout much of 2016. In January, the company’s PPS hovered around $0.84. By October, EXPI’s common stock climbed to a record high of more than $5.80 following the announcement of a new strategic partnership with Commissions, Inc., a leading provider of web-based real estate marketing and CRM software. The company’s stock is currently trading at around $4.35 per share.
News of EXPI’s retention of MZ Group comes just days after the company’s real estate brokerage division was recognized as a winner of the Oklahoma 2016 Top Workplaces Award by The Oklahoman newspaper. eXp Realty has previously received similar recognition in both Washington, D.C. and Atlanta for its commitment to creating a collaborative, engaging and rewarding work environment.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, December 14, 2016
Monaker Group, Inc. (MKGI) Making Travel Planning Easier Through Its Flagship NextTrip.com
According to 4Hoteliers (http://dtn.fm/zOeA9), 85% of travelers across the world are also smartphone users. The article goes on to state that 32% of these travelers use their mobile devices to book travel-related services. The company’s recent webinar, ‘Digital Marketing and Mobile Trends Impacting the Travel Industry’, showed that over 70% of travelers use mobile devices to check their itineraries.
But the increase in mobile usage for travel is not all that is impacting the industry. A more experience-based economy, the new social ecosystem we live in, and the growing preference for recommendations from peers are just some of the digital marketing trends transforming the travel industry, according to Smart Insights (http://dtn.fm/DoC4q). Because travel arrangements are now largely made via the Internet, and the typical consumer is looking for more than just a basic holiday, organizations in the travel industry are having to adapt to a more digital and mobile way of reaching consumers.
During a survey undertaken by Opera Mediaworks (http://dtn.fm/J9gWx), one in three people said that the availability of booking apps would make them more likely to book via mobile, and one in three also said that having research apps available could make them more likely to engage in more travel activities such as eating out, visiting various sights, and more. According to the ‘How People Use Their Phones For Travel’ research published by Google (http://dtn.fm/B5iX2), the top motivating factor for downloading travel apps is to make a specific activity or task easier. Users shared that what they find most valuable about travel apps is the wide range of features and the fact that apps store preferences that make future activities easier.
As a result, NextTrip.com, flagship company of Monaker Group, Inc. (OTCQB: MKGI), designed its own all-in-one travel planner, which gives travelers access to a range of free tools that allow them to import all booking details into one space. The free travel organizer allows users to discover hotels, restaurants, sights, and activities near their points of interest. The all-in-one travel planner helps holidaymakers organize details of their trips, and even split and collect money between groups of people. NextTrip’s travel planner is easy to use, easily accessible, and makes planning a trip while on the move simple thanks to its compatibility with mobile devices.
For more information, visit www.MonakerGroup.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
But the increase in mobile usage for travel is not all that is impacting the industry. A more experience-based economy, the new social ecosystem we live in, and the growing preference for recommendations from peers are just some of the digital marketing trends transforming the travel industry, according to Smart Insights (http://dtn.fm/DoC4q). Because travel arrangements are now largely made via the Internet, and the typical consumer is looking for more than just a basic holiday, organizations in the travel industry are having to adapt to a more digital and mobile way of reaching consumers.
During a survey undertaken by Opera Mediaworks (http://dtn.fm/J9gWx), one in three people said that the availability of booking apps would make them more likely to book via mobile, and one in three also said that having research apps available could make them more likely to engage in more travel activities such as eating out, visiting various sights, and more. According to the ‘How People Use Their Phones For Travel’ research published by Google (http://dtn.fm/B5iX2), the top motivating factor for downloading travel apps is to make a specific activity or task easier. Users shared that what they find most valuable about travel apps is the wide range of features and the fact that apps store preferences that make future activities easier.
As a result, NextTrip.com, flagship company of Monaker Group, Inc. (OTCQB: MKGI), designed its own all-in-one travel planner, which gives travelers access to a range of free tools that allow them to import all booking details into one space. The free travel organizer allows users to discover hotels, restaurants, sights, and activities near their points of interest. The all-in-one travel planner helps holidaymakers organize details of their trips, and even split and collect money between groups of people. NextTrip’s travel planner is easy to use, easily accessible, and makes planning a trip while on the move simple thanks to its compatibility with mobile devices.
For more information, visit www.MonakerGroup.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
eXp World Holdings, Inc. (EXPI) Maintaining a Positive Outlook for the Real Estate Industry in the U.S.
eXp World Holdings, Inc. (OTCQB: EXPI), the holding company for the agent-owned cloud-brokerage eXp Realty LLC, is maintaining a positive attitude toward the coming year. Most recently, RISMedia (http://dtn.fm/6JKt6) published a study highlighting the fact that more real estate executives are confident about their own local economies than about the world economy. Yet many real estate executives are concerned about risks posed by rising costs for traditional real estate, especially if the market should slump.
eXp World Holdings, Inc. is of the same opinion, pointing out that expenditures on brick and mortar facilities would remain fixed in the face of falling profits. According to EXPI: “Physical brick and mortar offices are of diminishing utility but represent a steady and escalating expense that erodes profits.”
EXPI has therefore used the emergence of the Internet as a force to drive advertising, leads, and sales, without the need for brick and mortar offices. By becoming a cloud-based brokerage and adopting a number of cloud-based technologies, EXPI has been able to not only cut out redundant staffing costs but also cut down on ancillary costs such as utility bills, rent, CAM, and furnishings, which are associated with brick and mortar locations.
As a result of the organization’s ability, from the beginning, to evolve with technological advancement and reduce costs by adopting a cloud-based environment, EXPI was voted second on this year’s Top Workplaces list among small-employer winners, according to NewsOK (http://dtn.fm/U0od2). In addition, Fundamental Research Corp. (http://dtn.fm/0a6S1), a research firm that initiated coverage of eXp World Holdings in April 2016, updated its analysis of the company, giving EXPI a price target of $6.78 per share compared to its previous objective of $4.06. The upward revision is based on EXPI’s record third quarter revenues, the change in its long term projections, and its healthy balance sheet.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
eXp World Holdings, Inc. is of the same opinion, pointing out that expenditures on brick and mortar facilities would remain fixed in the face of falling profits. According to EXPI: “Physical brick and mortar offices are of diminishing utility but represent a steady and escalating expense that erodes profits.”
EXPI has therefore used the emergence of the Internet as a force to drive advertising, leads, and sales, without the need for brick and mortar offices. By becoming a cloud-based brokerage and adopting a number of cloud-based technologies, EXPI has been able to not only cut out redundant staffing costs but also cut down on ancillary costs such as utility bills, rent, CAM, and furnishings, which are associated with brick and mortar locations.
As a result of the organization’s ability, from the beginning, to evolve with technological advancement and reduce costs by adopting a cloud-based environment, EXPI was voted second on this year’s Top Workplaces list among small-employer winners, according to NewsOK (http://dtn.fm/U0od2). In addition, Fundamental Research Corp. (http://dtn.fm/0a6S1), a research firm that initiated coverage of eXp World Holdings in April 2016, updated its analysis of the company, giving EXPI a price target of $6.78 per share compared to its previous objective of $4.06. The upward revision is based on EXPI’s record third quarter revenues, the change in its long term projections, and its healthy balance sheet.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, December 13, 2016
eXp World Holdings, Inc. (EXPI) Announces eXp Realty’s Reception of the Oklahoma 2016 Top Workplaces Award
In a news release issued late Monday, eXp World Holdings, Inc. (OTCQB: EXPI) announced that eXp Realty, the company’s full-service real estate brokerage, was recently recognized as one of the top workplaces in the state of Oklahoma by The Oklahoman newspaper. Based upon feedback from workplace members gathered through independent surveys by both The Oklahoman and Workplace Dynamics, the Agent-Owned Cloud Brokerage® earned the second spot in the annual list’s small-employer category, joining an impressive roster of 17 ‘Top Workplaces’ newcomers.
“This is a tremendous honor for all of the agents and brokers who are on our team,” Micah Mruwat, the company’s broker and leader in Oklahoma City, stated in yesterday’s news release. “This award speaks to the collaborative, engaging and rewarding environment of our company, not just here but in and across all eXp markets.”
Indeed, eXp Realty’s recent success has spanned markets across the country. In June of this year, the company earned a spot on similar lists recognizing the top workplaces in Washington, D.C. and Atlanta. Notably, eXp Realty’s inclusion on The Atlanta Journal-Constitution list marked the second consecutive year that the company has been recognized as a top workplace in Georgia’s capital city. When speaking to eXp Realty’s recent success in achieving these honors, Jason Gesing, the brokerage’s chief executive officer, highlighted the quality of the company’s growing collection of agent-owners.
“The synergy among our agents and brokers in Oklahoma is reflective of strong leadership in the state but also demonstrates agent-ownership’s impact on organizational health, culture, and shared sense of purpose,” he stated in yesterday’s news release. “At eXp Realty, our agents are both our shareholders and our customers. Their voices ring loudest and their opinions matter most which is what makes this award, and each Top Workplace recognition, so meaningful.”
By creating a rewarding work environment for some of the top real estate professionals in the country, eXp Realty has also been able to record tremendous growth since the beginning of 2016. On January 1, the company reported a base of 864 agents across its markets in the United States and Canada. By November, this figure had expanded to more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. Upon the release of its third quarter fiscal results last month, EXPI gave prospective shareholders some insight into the financial ramifications of this strong market performance.
During the three-month period ended September 30, 2016, EXPI recorded total revenues of $15.7 million, a year-over-year increase of 112 percent. Likewise, the company’s cash and cash equivalents at the end of the quarter were up 110 percent from the comparable period of 2015. These results, when combined with EXPI’s healthy balance sheet, quickly caught the attention of industry analysts. Less than a week after the company released its Q3 results, independent research firm Fundamental Research Corp. updated its coverage of the company and raised its fair value estimate on EXPI from $4.06 to $6.78 per share (http://dtn.fm/WOyf0).
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
“This is a tremendous honor for all of the agents and brokers who are on our team,” Micah Mruwat, the company’s broker and leader in Oklahoma City, stated in yesterday’s news release. “This award speaks to the collaborative, engaging and rewarding environment of our company, not just here but in and across all eXp markets.”
Indeed, eXp Realty’s recent success has spanned markets across the country. In June of this year, the company earned a spot on similar lists recognizing the top workplaces in Washington, D.C. and Atlanta. Notably, eXp Realty’s inclusion on The Atlanta Journal-Constitution list marked the second consecutive year that the company has been recognized as a top workplace in Georgia’s capital city. When speaking to eXp Realty’s recent success in achieving these honors, Jason Gesing, the brokerage’s chief executive officer, highlighted the quality of the company’s growing collection of agent-owners.
“The synergy among our agents and brokers in Oklahoma is reflective of strong leadership in the state but also demonstrates agent-ownership’s impact on organizational health, culture, and shared sense of purpose,” he stated in yesterday’s news release. “At eXp Realty, our agents are both our shareholders and our customers. Their voices ring loudest and their opinions matter most which is what makes this award, and each Top Workplace recognition, so meaningful.”
By creating a rewarding work environment for some of the top real estate professionals in the country, eXp Realty has also been able to record tremendous growth since the beginning of 2016. On January 1, the company reported a base of 864 agents across its markets in the United States and Canada. By November, this figure had expanded to more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. Upon the release of its third quarter fiscal results last month, EXPI gave prospective shareholders some insight into the financial ramifications of this strong market performance.
During the three-month period ended September 30, 2016, EXPI recorded total revenues of $15.7 million, a year-over-year increase of 112 percent. Likewise, the company’s cash and cash equivalents at the end of the quarter were up 110 percent from the comparable period of 2015. These results, when combined with EXPI’s healthy balance sheet, quickly caught the attention of industry analysts. Less than a week after the company released its Q3 results, independent research firm Fundamental Research Corp. updated its coverage of the company and raised its fair value estimate on EXPI from $4.06 to $6.78 per share (http://dtn.fm/WOyf0).
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, December 9, 2016
MediWound Ltd. (MDWD) Receives Consensus Analysts Rating of ‘Buy’
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company in the business of developing, manufacturing, and globally commercializing products that treat severe burns and wounds. In 2012, MediWound’s innovative drug, NexoBrid™, a burn and wound eschar removal agent, was approved by the European Medicines Agency (EMA) via a centralized procedure. The drug was given orphan indication for removal of dead and damaged skin in adults with burns that are deep partial and full thickness thermal burns.
NexoBrid™ was launched throughout Europe and is now being used in patients with hospitalized burns and wounds. MediWound has initiated phase III clinical trials on NexoBrid™ in the U.S. and pediatric study. The company also has two other products in its pipeline: EscharEx, which is in its phase II study and is for use in patients with chronic wounds, and MWPC003, which is about to enter its phase I study and is for use in patients with connective tissues disorders.
In November of this year, MediWound Ltd. announced third quarter 2016 financial results for the three- and nine-month periods ended September 30, 2016. The company reported revenue for the quarter of $518,000, compared to just over $100,000 for the same quarter of 2015. This was put down to the growing sales of NexoBrid™. The nine-month period results showed total revenue of $1.1 million, compared to $0.3 million for the same nine-month period of the previous year. MDWD will be spending the remainder of 2016 investing primarily in sales and marketing activities relating to the further adoption of NexoBrid™ in Europe.
Aegis Capital Corp. (http://dtn.fm/l63Bn) initiated coverage on MediWound Ltd., giving the company a ‘Buy’ rating with a price target of $11 per share. This rating was given based on the fact that the company has made significant progress in the area of wound debridement. According to the report, MDWD’s NexoBrid™ is showing significantly faster, more selective, safer, and more cost efficient results compared to current treatments. The report also highlights the possibility for the company to integrate into the chronic wound care market with EscharEx and markets relating to connective tissue disorders with its pipeline product MWPC003.
Despite Zacks Investment Research lowering the company’s status from a ‘Buy’ rating to a ‘Hold’ rating, six other research analysts have given MDWD a ‘Buy’ rating, and Wells Fargo & Co. offered MediWound an ‘Outperform’ rating with a price target on the stock of $14. The company has a consensus ‘Buy’ rating with a consensus price target of $13.25, all according to Cerbat Gem Market News and Analysis (http://dtn.fm/Ch85p).
Institutional investors and hedge funds are now said to own over 27% of MediWound shares, after Migdal Insurance & Finance Holdings, Wells Fargo & Company MN, and Oppenheimer & Co. bought new positions in the company’s stock. Wellington Management Group LLP and United Services Automobile Association also increased their positions in MediWound. As of this writing, the company has a market cap of $107.17 million, with an enterprise value at $84.15 million, and shares currently selling at around $4.90 per share.
For more information, visit the company’s website at www.mediwound.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
NexoBrid™ was launched throughout Europe and is now being used in patients with hospitalized burns and wounds. MediWound has initiated phase III clinical trials on NexoBrid™ in the U.S. and pediatric study. The company also has two other products in its pipeline: EscharEx, which is in its phase II study and is for use in patients with chronic wounds, and MWPC003, which is about to enter its phase I study and is for use in patients with connective tissues disorders.
In November of this year, MediWound Ltd. announced third quarter 2016 financial results for the three- and nine-month periods ended September 30, 2016. The company reported revenue for the quarter of $518,000, compared to just over $100,000 for the same quarter of 2015. This was put down to the growing sales of NexoBrid™. The nine-month period results showed total revenue of $1.1 million, compared to $0.3 million for the same nine-month period of the previous year. MDWD will be spending the remainder of 2016 investing primarily in sales and marketing activities relating to the further adoption of NexoBrid™ in Europe.
Aegis Capital Corp. (http://dtn.fm/l63Bn) initiated coverage on MediWound Ltd., giving the company a ‘Buy’ rating with a price target of $11 per share. This rating was given based on the fact that the company has made significant progress in the area of wound debridement. According to the report, MDWD’s NexoBrid™ is showing significantly faster, more selective, safer, and more cost efficient results compared to current treatments. The report also highlights the possibility for the company to integrate into the chronic wound care market with EscharEx and markets relating to connective tissue disorders with its pipeline product MWPC003.
Despite Zacks Investment Research lowering the company’s status from a ‘Buy’ rating to a ‘Hold’ rating, six other research analysts have given MDWD a ‘Buy’ rating, and Wells Fargo & Co. offered MediWound an ‘Outperform’ rating with a price target on the stock of $14. The company has a consensus ‘Buy’ rating with a consensus price target of $13.25, all according to Cerbat Gem Market News and Analysis (http://dtn.fm/Ch85p).
Institutional investors and hedge funds are now said to own over 27% of MediWound shares, after Migdal Insurance & Finance Holdings, Wells Fargo & Company MN, and Oppenheimer & Co. bought new positions in the company’s stock. Wellington Management Group LLP and United Services Automobile Association also increased their positions in MediWound. As of this writing, the company has a market cap of $107.17 million, with an enterprise value at $84.15 million, and shares currently selling at around $4.90 per share.
For more information, visit the company’s website at www.mediwound.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Globus Medical, Inc. (GMED) Class A Stock Sees Significant Volume Spike Moving Into 2017
As an eventful year for Globus Medical, Inc. (NYSE: GMED) is nearing an end, the leading medical device company experienced a substantial surge in trading volume on December 06. Equities.com (http://dtn.fm/Rab1C) noted a 1.3% gain of Globus Medical, Inc. Class A stock, closing at $23.31. The stock, which averages a daily volume of 1.11 million shares over the last month, captured the attention of numerous institutional investors and analysts when a surge of 11.57 million shares traded hands on 28,116 trades. The article states, “Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price.”
Increased awareness has been building for the medical device company during 2016, including the unveiling of its investigational robotics system Excelsius at the 2016 North American Spine Society (NASS) meeting held in late October. Per articles from MassDevice.com (http://dtn.fm/Of7Fc), and Becker’s Spine Review (http://dtn.fm/9t2Mm), Globus Medical expressed its anticipation of an approval and launch of the platform in early to mid-2017 to investment bank Leerink Partners. The MassDevice.com article also states that Leerink spoke with surgeons who were very interested in a trial of the platform as it becomes available. This adds credence to the company’s position as one of the “three main players” in the burgeoning surgical robotics industry (http://dtn.fm/u9oeH), citing recent commentary from the Medical Device and Diagnostic Industry website. MDDI mentions that surgical robots are only used in roughly 5% of spine procedures today, but that a survey by RBC Capital Markets indicates the potential for rapid adoption growth.
This potential for mass adoption has also been noted by financial analysis firm, Aegis Capital (http://dtn.fm/s1Rhi), in a report from November 30th that preceded Tuesday’s surge in trading activity. The firm set a $31 target price that was achieved, in part, by Globus Medical’s promising pipeline of emerging technologies, namely the robotics platform and trauma. The report calls attention to the system’s ability to serve as a competitor to Medtronic’s O-Arm with Stealth Station navigation. Those systems, which do not include robotic assistance, retail for more than $1 million, placing Globus Medical in a position to charge a premium on its own systems, as they incorporate full feature navigation. As a result, the company believes the customers of the roughly 900 O-Arms installed worldwide to be prospective customers and early adopters. Globus Medical intends to demonstrate, through clinical studies, the system’s time and money-saving benefits, as well as the added layer of predictability and accuracy it affords.
Headquartered in Audubon, Pennsylvania, Globus Medical, Inc. is a leading musculoskeletal implant manufacturer with the singular focus of advancing spinal surgery through the development of innovative engineering and technology. To date, Globus Medical has developed and released more than 150 spine products.
For additional information, visit www.GlobusMedical.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Increased awareness has been building for the medical device company during 2016, including the unveiling of its investigational robotics system Excelsius at the 2016 North American Spine Society (NASS) meeting held in late October. Per articles from MassDevice.com (http://dtn.fm/Of7Fc), and Becker’s Spine Review (http://dtn.fm/9t2Mm), Globus Medical expressed its anticipation of an approval and launch of the platform in early to mid-2017 to investment bank Leerink Partners. The MassDevice.com article also states that Leerink spoke with surgeons who were very interested in a trial of the platform as it becomes available. This adds credence to the company’s position as one of the “three main players” in the burgeoning surgical robotics industry (http://dtn.fm/u9oeH), citing recent commentary from the Medical Device and Diagnostic Industry website. MDDI mentions that surgical robots are only used in roughly 5% of spine procedures today, but that a survey by RBC Capital Markets indicates the potential for rapid adoption growth.
This potential for mass adoption has also been noted by financial analysis firm, Aegis Capital (http://dtn.fm/s1Rhi), in a report from November 30th that preceded Tuesday’s surge in trading activity. The firm set a $31 target price that was achieved, in part, by Globus Medical’s promising pipeline of emerging technologies, namely the robotics platform and trauma. The report calls attention to the system’s ability to serve as a competitor to Medtronic’s O-Arm with Stealth Station navigation. Those systems, which do not include robotic assistance, retail for more than $1 million, placing Globus Medical in a position to charge a premium on its own systems, as they incorporate full feature navigation. As a result, the company believes the customers of the roughly 900 O-Arms installed worldwide to be prospective customers and early adopters. Globus Medical intends to demonstrate, through clinical studies, the system’s time and money-saving benefits, as well as the added layer of predictability and accuracy it affords.
Headquartered in Audubon, Pennsylvania, Globus Medical, Inc. is a leading musculoskeletal implant manufacturer with the singular focus of advancing spinal surgery through the development of innovative engineering and technology. To date, Globus Medical has developed and released more than 150 spine products.
For additional information, visit www.GlobusMedical.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Thursday, December 8, 2016
Intellipharmaceutics International, Inc. (IPCI) Receives Aegis Update
Intellipharmaceutics International, Inc. (NASDAQ: IPCI) is a pharmaceutical company in the business of researching, developing, and manufacturing new and generic controlled and targeted release oral solid dosage drugs. The company has a large product portfolio which all follow a New Drug Application (NDA) 505(b)(2) U.S. Food and Drug Administration (FDA) regulatory pathway. The company’s controlled-release generic products follow an Abbreviated New Drug Application (ANDA) pathway.
IPCI currently has 11 products in the pipeline, more than half of which have either been filed for FDA approval or have already been approved. Two products, Regabatin™ XR and Carvedilol, are still in clinical trial stages. The company utilizes its patented Hypermatrix™ technology as a drug delivery platform that can be used to efficiently develop an array of new and existing pharmaceuticals. IPCI’s portfolio covers therapeutics areas such as pain, neurology, cardiovascular, diabetes, and gastrointestinal tract.
In October of this year, Intellipharmaceutics International released its financial results for the fiscal quarter ended August 31, 2016. During the quarter, IPCI reported revenues of $600,000 relating to its license and commercialization agreement with Par Pharmaceuticals, Inc. At this time, the company also announced the tentative approval by the FDA of its generic Seroquel XR®. Additionally, IPCI announced that it had signed an exclusive license and commercial supply agreement with Mallinckrodt, LLC for its generic Lamictal® XR™, Seroquel® and Pristiq®.
Between May 31, 2016 and August 31, 2016, the company reported an increase in cash of $1.8 million. Intellipharmaceutics International, Inc. reported a cash balance of $4.5 million after the $3 million payment from Mallinckrodt. As a result of this recent activity, Aegis Capital Corp. (http://dtn.fm/zD6vt) offered a company update, giving IPCI a ‘Buy’ rating with a price target of $8 per share. The update was released after the company submitted an NDA for abuse-deterrent Rexista extended release tablets. In addition, Intellipharmaceutics International has developed a system to pair with Rexista in order to deter opioid abuse, which has been declared as an epidemic by the CDC.
According to the Cerbat Gem Market News and Analysis (http://dtn.fm/D3r4V), other equities research analysts, such as Maxim Group and Brean Capital, also gave the company a ‘Buy’ rating with price targets of $6 and $8 per share, respectively. Institutional investor Morgan Stanley raised its position in the company by over 4%, giving it just below 62,000 shares of IPCI worth $130,000. Hedge funds and institutional investors now own 1.68% of Intellipharmaceutics International, Inc., and the company’s market cap currently stands at $84.29 million.
For more information, visit the company’s website at www.intellipharmaceutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
IPCI currently has 11 products in the pipeline, more than half of which have either been filed for FDA approval or have already been approved. Two products, Regabatin™ XR and Carvedilol, are still in clinical trial stages. The company utilizes its patented Hypermatrix™ technology as a drug delivery platform that can be used to efficiently develop an array of new and existing pharmaceuticals. IPCI’s portfolio covers therapeutics areas such as pain, neurology, cardiovascular, diabetes, and gastrointestinal tract.
In October of this year, Intellipharmaceutics International released its financial results for the fiscal quarter ended August 31, 2016. During the quarter, IPCI reported revenues of $600,000 relating to its license and commercialization agreement with Par Pharmaceuticals, Inc. At this time, the company also announced the tentative approval by the FDA of its generic Seroquel XR®. Additionally, IPCI announced that it had signed an exclusive license and commercial supply agreement with Mallinckrodt, LLC for its generic Lamictal® XR™, Seroquel® and Pristiq®.
Between May 31, 2016 and August 31, 2016, the company reported an increase in cash of $1.8 million. Intellipharmaceutics International, Inc. reported a cash balance of $4.5 million after the $3 million payment from Mallinckrodt. As a result of this recent activity, Aegis Capital Corp. (http://dtn.fm/zD6vt) offered a company update, giving IPCI a ‘Buy’ rating with a price target of $8 per share. The update was released after the company submitted an NDA for abuse-deterrent Rexista extended release tablets. In addition, Intellipharmaceutics International has developed a system to pair with Rexista in order to deter opioid abuse, which has been declared as an epidemic by the CDC.
According to the Cerbat Gem Market News and Analysis (http://dtn.fm/D3r4V), other equities research analysts, such as Maxim Group and Brean Capital, also gave the company a ‘Buy’ rating with price targets of $6 and $8 per share, respectively. Institutional investor Morgan Stanley raised its position in the company by over 4%, giving it just below 62,000 shares of IPCI worth $130,000. Hedge funds and institutional investors now own 1.68% of Intellipharmaceutics International, Inc., and the company’s market cap currently stands at $84.29 million.
For more information, visit the company’s website at www.intellipharmaceutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Revance Therapeutics, Inc. (RVNC) is “One to Watch”
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company focused on the development, commercialization, and manufacture of botulinum toxin products for use in aesthetic and therapeutic indications, including dermatology and neurology, recently announced its operating results for the third quarter of 2016 ended September 30.
A summary of the company’s financial results highlighted research and development expenses of $10.3 million for the three-month period, $2.7 million less than in the same quarter of 2015. The decrease in expenses was largely attributable to a reduction in clinical trial activities. Research and development costs for the nine-month period were up $5.3 million.
The increase in overall expenses for the company came from an increase in personnel costs and manufacturing activities. In addition, the company recently acquired the necessary patents for botulinum toxin and put forward patent applications for Botulinum Toxin Research Associates, Inc. (BTRX).
On November 29, Aegis Capital Corp. (http://dtn.fm/b4cKx) initiated coverage on Revance Therapeutics, Inc., giving the company a ‘Buy’ rating with a price target of $28 per share. Aegis gave the ‘Buy’ rating based on the company’s opportunity to tap into the $3 billion botulinum toxin market, which is expected to reach $5.6 billion by 2020.
With Botox currently holding approximately 85% of the market share, Aegis reported that RT002, RVNC’s drug candidate for the treatment of moderate to severe glabellar lines in adults, will likely stand out from competitors in the market. This has been put down to the fact that, unlike other drugs, RT002 targets specific areas, effectively limiting its spread to other regions.
Aegis expects RT002 to gain a market share of approximately 21% by 2025, as long as phase III trials prove to be as positive as the company’s phase II BELMONT study. RT002 is also currently being evaluated as a potential treatment for plantar fasciitis, a condition for which corticosteroids are the first method of treatment. As a result, the drug could also be the first of its kind to gain FDA approval for this indication.
Other analysts have also taken an interest in Revance. According to Cerbat Gem Market News and Analysis (http://dtn.fm/GR6xu), “two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock.”
Reiterating the optimism regarding Revance’s forward growth potential, a number of large investors have recently increased their stakes in the company. BlackRock Group Ltd., BlackRock Advisors LLC, FineMark National Bank & Trust, and American International Group, Inc. all raised their positions in Revance during the second and third quarters of this year by 4.3%, 15.8%, 750% and 10.9%, respectively. At close of market yesterday, the stock was selling at $16.80 per share.
For more information, visit the company’s website at www.revance.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
A summary of the company’s financial results highlighted research and development expenses of $10.3 million for the three-month period, $2.7 million less than in the same quarter of 2015. The decrease in expenses was largely attributable to a reduction in clinical trial activities. Research and development costs for the nine-month period were up $5.3 million.
The increase in overall expenses for the company came from an increase in personnel costs and manufacturing activities. In addition, the company recently acquired the necessary patents for botulinum toxin and put forward patent applications for Botulinum Toxin Research Associates, Inc. (BTRX).
On November 29, Aegis Capital Corp. (http://dtn.fm/b4cKx) initiated coverage on Revance Therapeutics, Inc., giving the company a ‘Buy’ rating with a price target of $28 per share. Aegis gave the ‘Buy’ rating based on the company’s opportunity to tap into the $3 billion botulinum toxin market, which is expected to reach $5.6 billion by 2020.
With Botox currently holding approximately 85% of the market share, Aegis reported that RT002, RVNC’s drug candidate for the treatment of moderate to severe glabellar lines in adults, will likely stand out from competitors in the market. This has been put down to the fact that, unlike other drugs, RT002 targets specific areas, effectively limiting its spread to other regions.
Aegis expects RT002 to gain a market share of approximately 21% by 2025, as long as phase III trials prove to be as positive as the company’s phase II BELMONT study. RT002 is also currently being evaluated as a potential treatment for plantar fasciitis, a condition for which corticosteroids are the first method of treatment. As a result, the drug could also be the first of its kind to gain FDA approval for this indication.
Other analysts have also taken an interest in Revance. According to Cerbat Gem Market News and Analysis (http://dtn.fm/GR6xu), “two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock.”
Reiterating the optimism regarding Revance’s forward growth potential, a number of large investors have recently increased their stakes in the company. BlackRock Group Ltd., BlackRock Advisors LLC, FineMark National Bank & Trust, and American International Group, Inc. all raised their positions in Revance during the second and third quarters of this year by 4.3%, 15.8%, 750% and 10.9%, respectively. At close of market yesterday, the stock was selling at $16.80 per share.
For more information, visit the company’s website at www.revance.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The Trade Desk, Inc. (TTD) is “One to Watch”
The Trade Desk, Inc. (NASDAQ: TTD) is a technology company that allows buyers to use proprietary data to better target their advertising dollars. With The Trade Desk platform, organizations are able to use fully automated and programmatic means to buy advertising space on a range of media where specific consumers are more likely to use their products or services. Organizations are able to create, manage, and optimize digital advertising campaigns in formats such as display, video, audio, and more.
Headquartered in Ventura, California, with other offices in the U.S, Europe, and Asia, TTD offers an integrated feature set to its customers that includes omnichannel targeting, data management that gives insight into audiences, enterprise APIS, and HD reporting. The company runs through a self-service, cloud-based platform, offering services across a multitude of devices, including mobile devices, computers, and television.
Most recently, The Trade Desk, Inc. was ranked number 55 on the Deloitte’s 2016 Technology Fast 500™ (http://dtn.fm/ai7PI) list of the fastest growing media, telecommunications, technology, energy, and life science companies in North America. The ranking for both private and public companies is based on the percentage of fiscal year growth between 2012 and 2015. TTD grew by over 1,800% during that period.
Earlier in November, The Trade Desk reported its financial results for the third quarter of 2016 (http://dtn.fm/UNu7p). Since becoming a public company in September, the company reported an increase of over 80% in revenue. Revenue for the third quarter came in at $53 million, compared to $28.8 million during the third quarter of 2015.
Highlights of the report included the fact that TTD’s customer retention rate was over 95% for the quarter, and the company is expanding with new offices expected in Orange County, California, and Hong Kong, alongside plans to open new offices in both Europe and Asia Pacific. The company is aiming to report revenues of up to $62 million for the fourth quarter of 2016 and an adjusted EBITDA margin of 30%.
According to Cerbat Gem Market News and Analysis (http://dtn.fm/Shg8w), The Trade Desk’s report of $0.24 earnings per share for the quarter was higher than Thomson Reuters’ consensus estimate by $0.03. Equities research analysts have made predictions of $0.85 EPS for the company for the current fiscal year.
Jefferies Group and Cantor Fitzgerald gave The Trade Desk a ‘Buy’ rating with target prices on the stock of $35 and $30, respectively. The company received a consensus ‘Buy’ rating with an average price target of $33.13.
For more information, visit the company’s website at www.thetradedesk.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Headquartered in Ventura, California, with other offices in the U.S, Europe, and Asia, TTD offers an integrated feature set to its customers that includes omnichannel targeting, data management that gives insight into audiences, enterprise APIS, and HD reporting. The company runs through a self-service, cloud-based platform, offering services across a multitude of devices, including mobile devices, computers, and television.
Most recently, The Trade Desk, Inc. was ranked number 55 on the Deloitte’s 2016 Technology Fast 500™ (http://dtn.fm/ai7PI) list of the fastest growing media, telecommunications, technology, energy, and life science companies in North America. The ranking for both private and public companies is based on the percentage of fiscal year growth between 2012 and 2015. TTD grew by over 1,800% during that period.
Earlier in November, The Trade Desk reported its financial results for the third quarter of 2016 (http://dtn.fm/UNu7p). Since becoming a public company in September, the company reported an increase of over 80% in revenue. Revenue for the third quarter came in at $53 million, compared to $28.8 million during the third quarter of 2015.
Highlights of the report included the fact that TTD’s customer retention rate was over 95% for the quarter, and the company is expanding with new offices expected in Orange County, California, and Hong Kong, alongside plans to open new offices in both Europe and Asia Pacific. The company is aiming to report revenues of up to $62 million for the fourth quarter of 2016 and an adjusted EBITDA margin of 30%.
According to Cerbat Gem Market News and Analysis (http://dtn.fm/Shg8w), The Trade Desk’s report of $0.24 earnings per share for the quarter was higher than Thomson Reuters’ consensus estimate by $0.03. Equities research analysts have made predictions of $0.85 EPS for the company for the current fiscal year.
Jefferies Group and Cantor Fitzgerald gave The Trade Desk a ‘Buy’ rating with target prices on the stock of $35 and $30, respectively. The company received a consensus ‘Buy’ rating with an average price target of $33.13.
For more information, visit the company’s website at www.thetradedesk.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
National Waste Management Holdings, Inc. (NWMH) Featured in NetworkNewsWire Exclusive Audio Interview
Before the opening bell, NetworkNewsWire (NNW), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, announced the online availability of an exclusive interview with National Waste Management Holdings, Inc. (OTC: NWMH).
NNW’s communications solutions include social communications, news aggregation and syndication as well as enhanced news release services designed to introduce private and public companies to a wide range of audiences. Leveraging a network of more than 5,000 key distribution outlets, NNW gives its clients a voice – be it through audio interview, video production or other tailored means – to better communicate with the investment community.
National Waste CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor capitalized on the platform provided by NNW by speaking toward National Waste’s rapidly growing presence in the East Coast solid waste management industry, which is being spurred on by an aggressive, acquisition-based business model.
The full interview can be heard by visiting http://nnw.fm/nwmh-interview-dec-2016
“Our goal is to do one acquisition a quarter, and we are going to meet that goal,” Paveglio told host Stuart Smith in the interview. “We plan on finishing one up here in the fourth quarter and in 2017 we already have a couple acquisitions that we are doing due diligence on and we intend to roll those in on the first two quarters of 2017.”
CFO Dali Kranzthor echoed this sentiment by highlighting some of the advantages presented by two key acquisitions the company completed in 2015. He also reflected on National Waste’s current corporate goal of becoming vertically integrated.
“We had two key acquisitions that occurred at the end of 2015; two that we did in rapid succession … each one of those almost doubled the company and it also gave us a giant geographic footprint in upstate New York,” Kranzthor added. “The other goal here is to become completely vertically integrated. The highest profitability and the highest margins are when you can take the garbage collection all the way cradle to grave. Very few players in this market have the ability to vertically integrate and have the funds and infrastructure … Only the biggest and the best have the ability to pull that off and so we’re emulating that with our current acquisitions.”
Looking toward 2017, the National Waste executives spoke to the importance of maintaining and broadening relationships with financiers in order to fund acquisitions while continuing to relay the company’s corporate message to investors.
“The exciting thing is that this industry of waste management has a lot of eyes on it and we’ve seen … some amazing acquisitions at the very top level,” concluded Kranzthor. “As a leading company in this space we see that we’re going to basically stumble upon many more opportunities … It’s a very exciting industry and I think over the next couple of years we’re going to see a lot of highlights in this area and a lot more people are going to see us high on the radar.”
National Waste is a growing solid waste management company serving Florida’s west coast and upstate New York with comprehensive solutions for full waste diversion. The company’s current operations center on its 54-acre landfill facility located in Hernando, Florida, which handles average disposals of roughly 240,000 cubic yards of construction debris each year and is already permitted for future expansion. National Waste also offers ancillary services, such as roll-off dumpster services, recycling and retail mulching services.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
NNW’s communications solutions include social communications, news aggregation and syndication as well as enhanced news release services designed to introduce private and public companies to a wide range of audiences. Leveraging a network of more than 5,000 key distribution outlets, NNW gives its clients a voice – be it through audio interview, video production or other tailored means – to better communicate with the investment community.
National Waste CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor capitalized on the platform provided by NNW by speaking toward National Waste’s rapidly growing presence in the East Coast solid waste management industry, which is being spurred on by an aggressive, acquisition-based business model.
The full interview can be heard by visiting http://nnw.fm/nwmh-interview-dec-2016
“Our goal is to do one acquisition a quarter, and we are going to meet that goal,” Paveglio told host Stuart Smith in the interview. “We plan on finishing one up here in the fourth quarter and in 2017 we already have a couple acquisitions that we are doing due diligence on and we intend to roll those in on the first two quarters of 2017.”
CFO Dali Kranzthor echoed this sentiment by highlighting some of the advantages presented by two key acquisitions the company completed in 2015. He also reflected on National Waste’s current corporate goal of becoming vertically integrated.
“We had two key acquisitions that occurred at the end of 2015; two that we did in rapid succession … each one of those almost doubled the company and it also gave us a giant geographic footprint in upstate New York,” Kranzthor added. “The other goal here is to become completely vertically integrated. The highest profitability and the highest margins are when you can take the garbage collection all the way cradle to grave. Very few players in this market have the ability to vertically integrate and have the funds and infrastructure … Only the biggest and the best have the ability to pull that off and so we’re emulating that with our current acquisitions.”
Looking toward 2017, the National Waste executives spoke to the importance of maintaining and broadening relationships with financiers in order to fund acquisitions while continuing to relay the company’s corporate message to investors.
“The exciting thing is that this industry of waste management has a lot of eyes on it and we’ve seen … some amazing acquisitions at the very top level,” concluded Kranzthor. “As a leading company in this space we see that we’re going to basically stumble upon many more opportunities … It’s a very exciting industry and I think over the next couple of years we’re going to see a lot of highlights in this area and a lot more people are going to see us high on the radar.”
National Waste is a growing solid waste management company serving Florida’s west coast and upstate New York with comprehensive solutions for full waste diversion. The company’s current operations center on its 54-acre landfill facility located in Hernando, Florida, which handles average disposals of roughly 240,000 cubic yards of construction debris each year and is already permitted for future expansion. National Waste also offers ancillary services, such as roll-off dumpster services, recycling and retail mulching services.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Daktronics, Inc. (DAKT) is “One to Watch”
Daktronics, Inc. (NASDAQ: DAKT), a company that designs, manufactures, and sells electronic display systems and related products on a global scale, has been the topic of several reports since the company announced breaking into a new 52-week high on November 25, 2016. Equities.com (http://dtn.fm/hgd4G) announced shares for the company reached a peak of $10.78, closing at $10.64 after opening at $10.46, a move of over 2% is just one day.
As a result, Zacks Investment Research upgraded the company from a ‘Hold’ rating to a ‘Strong Buy’, with a target price of $12 per share. Needham & Company LLC reaffirmed a ‘Buy’ rating, with a target price of $11, up from $9.50 previously. Lastly, The Street raised the company’s rating from a ‘Hold’ rating to a ‘Buy’ rating.
Daktronics, Inc. released its second quarter fiscal 2017 results on November 22, 2016, reporting earnings of $170 million, over $8 million more than estimates set by analysts. The revenue for this quarter was up 7.8% compared to the same quarter last year, and DAKT reported a return on equity of just under 5% with a net margin of 1.64%, all according to The Cerbat Gem Market News and Analysis (http://dtn.fm/G5mK3).
In addition, various hedge funds have increased their stakes in the company. BlackRock Fund Advisors and BlackRock Institutional Trust Company N.A. have both increased their stakes in Daktronics, by 11% and 0.9%, respectively, giving them ownership of more than two million and 900,000 shares each. Vanguard Group, Inc. and Dimensional Fund Advisors LP also increased their stakes, giving them ownership of more than 1.8 million shares each. Lastly, State Street Corp. increased its stake in DAKT, giving it stock worth over $4.5 million. As a result, institutional investors and hedge funds now own over 46% of Daktronics stock.
On December 2, 2016, Daktronics announced that its board of directors approved a regular quarterly cash dividend of $0.07 per share, payable on December 23. This announcement was made very shortly after the company was awarded a multi-million dollar project by the state of Nevada, project NEON, which involves widening Interstate 15, the busiest road in Nevada.
For more information, visit the company’s website at www.daktronics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
As a result, Zacks Investment Research upgraded the company from a ‘Hold’ rating to a ‘Strong Buy’, with a target price of $12 per share. Needham & Company LLC reaffirmed a ‘Buy’ rating, with a target price of $11, up from $9.50 previously. Lastly, The Street raised the company’s rating from a ‘Hold’ rating to a ‘Buy’ rating.
Daktronics, Inc. released its second quarter fiscal 2017 results on November 22, 2016, reporting earnings of $170 million, over $8 million more than estimates set by analysts. The revenue for this quarter was up 7.8% compared to the same quarter last year, and DAKT reported a return on equity of just under 5% with a net margin of 1.64%, all according to The Cerbat Gem Market News and Analysis (http://dtn.fm/G5mK3).
In addition, various hedge funds have increased their stakes in the company. BlackRock Fund Advisors and BlackRock Institutional Trust Company N.A. have both increased their stakes in Daktronics, by 11% and 0.9%, respectively, giving them ownership of more than two million and 900,000 shares each. Vanguard Group, Inc. and Dimensional Fund Advisors LP also increased their stakes, giving them ownership of more than 1.8 million shares each. Lastly, State Street Corp. increased its stake in DAKT, giving it stock worth over $4.5 million. As a result, institutional investors and hedge funds now own over 46% of Daktronics stock.
On December 2, 2016, Daktronics announced that its board of directors approved a regular quarterly cash dividend of $0.07 per share, payable on December 23. This announcement was made very shortly after the company was awarded a multi-million dollar project by the state of Nevada, project NEON, which involves widening Interstate 15, the busiest road in Nevada.
For more information, visit the company’s website at www.daktronics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, December 7, 2016
eXp World Holdings, Inc. (EXPI) Creating a Legacy of Commercial and Social Impact
eXp World Holdings, Inc. (OTCQB: EXPI) is a corporation of the times and parent company to a selection of notable subsidiaries that are making a lasting impact, both commercially and socially. The most notable of these companies is eXp Realty LLC, a rapidly-growing, cloud-based brokerage with an agent base featuring more than 2,000 members.
The eXp Realty business model is a thing of beauty. The model has helped accelerate eXp Realty’s already significant growth throughout North America (since January 1, 2016, eXp Realty has added over 1,000 real estate professionals to its ranks and more than doubled its staff numbers) and led to eXp Realty being cited as a ‘brokerage of the future’ (http://dtn.fm/Y8P6p).
eXp Realty runs all of its operations remotely. From agent training to lead generation, leadership meetings, exchanges of ideas and experiences, IT services and more, every aspect of the business is run through a virtual reality platform. This complete embrace of ground-breaking technology, including virtual and augmented reality advancements, has helped the company form a close-knit community of real estate professionals who serve over 40 markets across the United States and Canada.
eXp Realty does a lot of things differently. Through its 3-D, fully-immersive, cloud office environment, agents and brokers can collaborate, train and socialize anywhere and anytime. Courtesy of their around-the-clock access to this office environment, they can stay connected from the comfort of their homes or while traveling abroad and, at the same time, erase all of the expenses typically linked to owning and running a physical office. This way, brokerage members are able to increase their profit margins without spending too much out of pocket and, simultaneously, provide more cost-effective services to their customers.
On the revenue side, the eXp Realty business model goes several steps further through aggressive and profitable revenue sharing programs. It offers its members the opportunity to earn equity rewards in exchange for their contributions to the company’s growth. Plus, both eXp Realty and eXp Realty of Canada pay agents a percentage of the gross commission income earned by colleagues they bring into the company.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The eXp Realty business model is a thing of beauty. The model has helped accelerate eXp Realty’s already significant growth throughout North America (since January 1, 2016, eXp Realty has added over 1,000 real estate professionals to its ranks and more than doubled its staff numbers) and led to eXp Realty being cited as a ‘brokerage of the future’ (http://dtn.fm/Y8P6p).
eXp Realty runs all of its operations remotely. From agent training to lead generation, leadership meetings, exchanges of ideas and experiences, IT services and more, every aspect of the business is run through a virtual reality platform. This complete embrace of ground-breaking technology, including virtual and augmented reality advancements, has helped the company form a close-knit community of real estate professionals who serve over 40 markets across the United States and Canada.
eXp Realty does a lot of things differently. Through its 3-D, fully-immersive, cloud office environment, agents and brokers can collaborate, train and socialize anywhere and anytime. Courtesy of their around-the-clock access to this office environment, they can stay connected from the comfort of their homes or while traveling abroad and, at the same time, erase all of the expenses typically linked to owning and running a physical office. This way, brokerage members are able to increase their profit margins without spending too much out of pocket and, simultaneously, provide more cost-effective services to their customers.
On the revenue side, the eXp Realty business model goes several steps further through aggressive and profitable revenue sharing programs. It offers its members the opportunity to earn equity rewards in exchange for their contributions to the company’s growth. Plus, both eXp Realty and eXp Realty of Canada pay agents a percentage of the gross commission income earned by colleagues they bring into the company.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monaker Group, Inc. (MKGI) Leveraging Game-Changing Approach to the Real-Time Alternative Lodging Market
The business model proposed by Monaker Group, Inc. (OTCQB: MKGI) and the group’s innovative approach to the alternative vacation rental market are discussed in depth by leading financial news and information portal SECFilings.com (http://dtn.fm/A5Mjn). Noting that Monaker Group, a technology-driven tourism company offering comprehensive travel solutions and personalized tours, has a unique position and approach to real-time alternative travel lodging reservations, the article goes on to explain how this business model is different and more efficient than others on the market.
According to Euromonitor data quoted by the article, global tourism is expected to have a modest compound annual growth rate of only four percent through 2019. However, the industry currently sits at $2.7 trillion and is ripe for innovative solutions and approaches. Some industry players have already begun to change their approach in their drive to engage and retain customers and drive sales. For instance, Priceline Group Inc. (NASDAQ: PCLN) has already changed how travelers book hotels and airfare, while Airbnb is questioning the need to actually use hotels when traveling and instead focusing on alternative lodging solutions.
While Airbnb remains an innovator in the field, the problem with its system is that most of the properties listed are not bookable in real time, the SECFilings.com article says. This means travelers looking for accommodation through the website must first wait for property owners to reply and confirm their bookings. While many budget travelers might not have a problem with that, tourists who have a tendency to plan their vacations in great detail usually look for a more seamless travel and accommodation experience, such as the one offered by a hotel.
Monaker Group, via its NextTrip.com booking platform, provides a solution to this dilemma by offering real-time booking options to travelers. The group has over 1.4 million alternative lodging rentals in its portfolio, properties spread throughout Asia, Europe, South America and the United States. By offering real-time booking, the group wants to solve a major problem on the alternative rentals market and to eventually integrate with airlines and online travel agencies so that they can provide access to alternative lodging options outside of the traditional hotel listings.
The NextTrip platform, launched in February of this year, offers travelers access to a large inventory of alternative lodging options, as well as hotels, tours, airlines, rental cars, and more. The NextTrip planner also allows users to import their bookmarks from other websites, look for tourist attractions in their vicinity, and even split the costs among their traveling party members based on each person’s participation.
Monaker Group has already sealed various partnerships with other travel industry companies to expand and integrate the NextTrip platform. Back in August, Monaker signed a deal with Mark Travel’s travel technology division, Trisept Solutions, to integrate its booking platform. Another step toward integrating real-time vacation rentals into the mainstream travel industry was taken earlier this month, when Monaker announced a new loyalty program and travel service as part of its partnership with Recruiter.com.
The SECFiling.com article further notes that Monaker Group’s ambitions don’t stop here, as the company’s management has plans to offer solutions for every challenge travelers face, with the goal of making the travel experience more seamless for every tourist using their services.
For more information, visit www.MonakerGroup.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
According to Euromonitor data quoted by the article, global tourism is expected to have a modest compound annual growth rate of only four percent through 2019. However, the industry currently sits at $2.7 trillion and is ripe for innovative solutions and approaches. Some industry players have already begun to change their approach in their drive to engage and retain customers and drive sales. For instance, Priceline Group Inc. (NASDAQ: PCLN) has already changed how travelers book hotels and airfare, while Airbnb is questioning the need to actually use hotels when traveling and instead focusing on alternative lodging solutions.
While Airbnb remains an innovator in the field, the problem with its system is that most of the properties listed are not bookable in real time, the SECFilings.com article says. This means travelers looking for accommodation through the website must first wait for property owners to reply and confirm their bookings. While many budget travelers might not have a problem with that, tourists who have a tendency to plan their vacations in great detail usually look for a more seamless travel and accommodation experience, such as the one offered by a hotel.
Monaker Group, via its NextTrip.com booking platform, provides a solution to this dilemma by offering real-time booking options to travelers. The group has over 1.4 million alternative lodging rentals in its portfolio, properties spread throughout Asia, Europe, South America and the United States. By offering real-time booking, the group wants to solve a major problem on the alternative rentals market and to eventually integrate with airlines and online travel agencies so that they can provide access to alternative lodging options outside of the traditional hotel listings.
The NextTrip platform, launched in February of this year, offers travelers access to a large inventory of alternative lodging options, as well as hotels, tours, airlines, rental cars, and more. The NextTrip planner also allows users to import their bookmarks from other websites, look for tourist attractions in their vicinity, and even split the costs among their traveling party members based on each person’s participation.
Monaker Group has already sealed various partnerships with other travel industry companies to expand and integrate the NextTrip platform. Back in August, Monaker signed a deal with Mark Travel’s travel technology division, Trisept Solutions, to integrate its booking platform. Another step toward integrating real-time vacation rentals into the mainstream travel industry was taken earlier this month, when Monaker announced a new loyalty program and travel service as part of its partnership with Recruiter.com.
The SECFiling.com article further notes that Monaker Group’s ambitions don’t stop here, as the company’s management has plans to offer solutions for every challenge travelers face, with the goal of making the travel experience more seamless for every tourist using their services.
For more information, visit www.MonakerGroup.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Professional Diversity Network, Inc. (IPDN) Helping Shape a More Demographic-Based Workforce
With diversity being both a legal and popular factor in business, and with businesses facing a more diverse customer base, companies are making a conscious effort to develop and maintain a more culturally diverse workforce. Immigration, politics, new generations, women in leadership, family dynamics, income, and a shift in religious beliefs are just some of the factors affecting diversity. According to the Pew Research Center (http://dtn.fm/9AhWg), America is expected to become significantly more ethnically diverse in the next 50 years, due partially to new Asian and Hispanic immigration.
With the U.S. and other countries becoming more diverse, new research has been underway surveying over 450 multi-million dollar companies across the globe looking at a total of 128 different aspects of talent management. According to a Forbes (http://dtn.fm/6KfWP) article, research shows that gender and ethnically diverse companies are more likely to outperform competitors by 15% and 35%, respectively. In addition, companies with women on their boards statistically outperform peers over longer time frames.
The mission of Professional Diversity Networks, Inc. (NASDAQ: IPDN) is to provide professionals a trusted network that pairs members with employers who are serious about creating a more diverse workforce, employers that value diversity within their companies. Professional Diversity Networks works off the principle that companies seek to meet the needs of an increasingly diverse customer base.
Network members looking for jobs can get started on their search with three simple steps: creating a profile, applying for jobs, and finding hiring employers. The technology IPDN offers allows for a more creative and productive job search due to the fact that employers on the site are looking to hire aspiring employees from a diverse range of backgrounds.
For more information, visit the company’s website at www.prodivnet.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
With the U.S. and other countries becoming more diverse, new research has been underway surveying over 450 multi-million dollar companies across the globe looking at a total of 128 different aspects of talent management. According to a Forbes (http://dtn.fm/6KfWP) article, research shows that gender and ethnically diverse companies are more likely to outperform competitors by 15% and 35%, respectively. In addition, companies with women on their boards statistically outperform peers over longer time frames.
The mission of Professional Diversity Networks, Inc. (NASDAQ: IPDN) is to provide professionals a trusted network that pairs members with employers who are serious about creating a more diverse workforce, employers that value diversity within their companies. Professional Diversity Networks works off the principle that companies seek to meet the needs of an increasingly diverse customer base.
Network members looking for jobs can get started on their search with three simple steps: creating a profile, applying for jobs, and finding hiring employers. The technology IPDN offers allows for a more creative and productive job search due to the fact that employers on the site are looking to hire aspiring employees from a diverse range of backgrounds.
For more information, visit the company’s website at www.prodivnet.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Tuesday, December 6, 2016
National Waste Management Holdings, Inc. (NWMH) Protects the Environment with a Range of Green Services
In the ‘Advancing Sustainable Materials Management: 2014 Fact Sheet’ (http://dtn.fm/JH1hf) published last month, the U.S. Environmental Protection Agency (EPA) released statistics on the amount of municipal solid waste (MSW) and construction and demolition (C&D) debris generated by U.S. households and businesses. The rising amounts pose a growing risk to the environment and to our health. The range of materials requiring disposal is also increasing.
Since the dawn of the electronic and digital ages, varieties of electronic waste (e-waste), which include computers and associated devices and materials, have multiplied. This mountain of waste poses a troubling challenge to the health of the planet and its inhabitants. Thankfully, it is a challenge that has been taken on by Florida-based National Waste Management Holdings (OTC: NWMH). National Waste is a growing solid waste management company that provides compliant, comprehensive solutions for full waste diversion while managing long-term partnerships with municipal, institutional, commercial and industrial customers.
The EPA Fact Sheet shows that, in 2014, the last year for which comprehensive data is available, Americans generated 258 million short tons (2,000 lbs) of MSW. MSW includes residential waste (including waste from multi-family housing) and waste from commercial and institutional locations, such as businesses, schools and hospitals. About 13 percent, or 33 million short tons, of that was burned as part of an energy recovery scheme. Another 89 million short tons, representing about 35 percent, was recycled and composted, and 136 million short tons, or 52.7 percent, went into landfills.
In addition to the mound of MSW, huge quantities of C&D debris are being generated. In 2014, 534 million tons of C&D debris were disposed of. Concrete composed the largest portion of this assortment, accounting for about 70 percent. Asphalt or blacktop comprised some 14 percent, and wood products made up seven percent. Other products accounted for nine percent combined. Over 90 percent of total C&D debris comes from demolition, naturally, while construction activities generate the other 10 percent. This is all good news for National Waste. When it comes to environmental protection, the company has a range of services that mark it out as decidedly green.
National Waste operates a licensed 54-acre landfill in Hernando, Florida, that disposes of roughly 240,000 cubic yards of construction debris annually. Landfill services include the disposal of C&D debris, asphalt and rock, lumber and wood, brick, wallboard, drywall and plaster, pallets, rock concrete, dirt, sand and uncontaminated soil, plumbing fixtures, non-asbestos insulation, roofing materials and shingles, glass, piping, waste metal, brush and land clearing, yard and tree waste and many electrical and wiring components.
To complement these landfill services, National Waste offers a range of roll off containers for rental. Containers with 20, 30 and 40 cubic yard capacity are available. The company also carries a line of recycled wood mulch and garden mulch, for which it provides bulk delivery service if needed. National Waste’s mulch is proprietary, manufactured from reclaimed and recycled wood at its landfills and transfer stations.
National Waste is also in the vanguard of the thrust by the state of Florida to achieve 75 percent recycling by 2020. The company is looking to transform its services, as well as its fundamental business model, to include a portable picking station in order to meet that objective. The implementation of a portable sorting line at the landfill will enable National Waste to increase its recyclables rate.
National Waste will also start picking clean dimensional lumber, which can be sold to wood pellet producers. The picking station will increase its concrete recycling program by about 25 percent. Additionally, cardboard and shrink-wrap plastic will be baled. The company believes the market for shingles as a fuel and asphalt blend will be growing with momentum in the next year and is dedicated to recycling as much as it can from all of its services.
This aggressive strategy is already showing signs of success. Revenues for the third quarter ended September 2016 were $1.8 million. This represented a 269 percent rise over the third quarter 2015 figure of $0.5 million. Revenues for the nine-month period ended September 2016 were $4.9 million, representing similar growth over 2015 same period revenues of $1.3 million.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Since the dawn of the electronic and digital ages, varieties of electronic waste (e-waste), which include computers and associated devices and materials, have multiplied. This mountain of waste poses a troubling challenge to the health of the planet and its inhabitants. Thankfully, it is a challenge that has been taken on by Florida-based National Waste Management Holdings (OTC: NWMH). National Waste is a growing solid waste management company that provides compliant, comprehensive solutions for full waste diversion while managing long-term partnerships with municipal, institutional, commercial and industrial customers.
The EPA Fact Sheet shows that, in 2014, the last year for which comprehensive data is available, Americans generated 258 million short tons (2,000 lbs) of MSW. MSW includes residential waste (including waste from multi-family housing) and waste from commercial and institutional locations, such as businesses, schools and hospitals. About 13 percent, or 33 million short tons, of that was burned as part of an energy recovery scheme. Another 89 million short tons, representing about 35 percent, was recycled and composted, and 136 million short tons, or 52.7 percent, went into landfills.
In addition to the mound of MSW, huge quantities of C&D debris are being generated. In 2014, 534 million tons of C&D debris were disposed of. Concrete composed the largest portion of this assortment, accounting for about 70 percent. Asphalt or blacktop comprised some 14 percent, and wood products made up seven percent. Other products accounted for nine percent combined. Over 90 percent of total C&D debris comes from demolition, naturally, while construction activities generate the other 10 percent. This is all good news for National Waste. When it comes to environmental protection, the company has a range of services that mark it out as decidedly green.
National Waste operates a licensed 54-acre landfill in Hernando, Florida, that disposes of roughly 240,000 cubic yards of construction debris annually. Landfill services include the disposal of C&D debris, asphalt and rock, lumber and wood, brick, wallboard, drywall and plaster, pallets, rock concrete, dirt, sand and uncontaminated soil, plumbing fixtures, non-asbestos insulation, roofing materials and shingles, glass, piping, waste metal, brush and land clearing, yard and tree waste and many electrical and wiring components.
To complement these landfill services, National Waste offers a range of roll off containers for rental. Containers with 20, 30 and 40 cubic yard capacity are available. The company also carries a line of recycled wood mulch and garden mulch, for which it provides bulk delivery service if needed. National Waste’s mulch is proprietary, manufactured from reclaimed and recycled wood at its landfills and transfer stations.
National Waste is also in the vanguard of the thrust by the state of Florida to achieve 75 percent recycling by 2020. The company is looking to transform its services, as well as its fundamental business model, to include a portable picking station in order to meet that objective. The implementation of a portable sorting line at the landfill will enable National Waste to increase its recyclables rate.
National Waste will also start picking clean dimensional lumber, which can be sold to wood pellet producers. The picking station will increase its concrete recycling program by about 25 percent. Additionally, cardboard and shrink-wrap plastic will be baled. The company believes the market for shingles as a fuel and asphalt blend will be growing with momentum in the next year and is dedicated to recycling as much as it can from all of its services.
This aggressive strategy is already showing signs of success. Revenues for the third quarter ended September 2016 were $1.8 million. This represented a 269 percent rise over the third quarter 2015 figure of $0.5 million. Revenues for the nine-month period ended September 2016 were $4.9 million, representing similar growth over 2015 same period revenues of $1.3 million.
For more information, visit the company’s website at www.nationalwastemgmt.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cellceutix Corp. (CTIX) Advances Pipeline toward Multi-billion Dollar Opportunities, Piques Peer Interest along the Way
Cellceutix (OTCQB: CTIX) CEO Leo Ehrlich in September issued a fiscal year-end business statement recapping the company’s ability to usher its three unique compounds through various stages of clinical trials to successfully meet primary endpoints and drop anchors in several key markets. Advancements of its current pipeline – spanning dermatology, cancer, infectious disease and gastrointestinal indications – also set the company on course to achieve another season of remarkable progress.
Cellceutix’s lead cancer drug candidate is Kevetrin™, an Orphan Drug anti-cancer agent entering phase 2a clinical trials for the treatment of ovarian cancer. Upon commercialization, Kevetrin would be the world’s first p53-modulating drug. The company is also conducting research to develop an oral formulation of Kevetrin, taking advantage of the drug’s short half-life of roughly two hours.
“If we can develop an oral Kevetrin dosing possibilities are numerous. Perhaps two times or three times a day and seven days a week. Now you know why we are excited. A drug activating p53 and dosed orally, we think would have blockbuster potential. More research needs to be done to validate the clinical effectiveness of Kevetrin as well as developing an oral formulation. But I’d hope investors now understand why we get excited about the possibility of developing both the world’s first safe p53 modulating drug and an oral formulation,” Ehrlich stated in the company’s fiscal Q1 2017 earnings call in September (http://dtn.fm/2l0JR).
Another propellant of progress is an anti-psoriasis drug candidate the company once called a “dark horse” or “long shot.” Advancing through two successful clinical trials, however, the potential of Cellceutix’s Prurisol™, now in phase 2b trials, is starting to take shape.
“We believe that the potential safety profile of Prurisol may make this an attractive alternative to Celgene’s (NYSE: CELG) OTEZLA, which is on its way to achieving $1 billion in sales within just three years of its launch,” Arthur P. Bertolino, MD, PhD, MBA, president and chief medical officer at Cellceutix, stated in a recent news release.
In the previously mentioned September business update, Ehlrich also noted Allergan’s (NYSE: AGN) $639 million acquisition of Vitae Pharmaceuticals’ (NASDAQ: VTAE) two clinical drug candidates, one of which is an oral therapy for psoriasis (http://dtn.fm/JJ3mQ).
“I share this with you because it exemplifies the premium that the industry is placing on new, oral psoriasis drugs, even those in mid-stage development. I’m not in the business of analysis, but it seems to me that Allergan values VTP-43742 at more than our total market capitalization. As such, we see a tremendous market opportunity with Prurisol and greatly look forward to initiating our Phase 2b trial in patients with moderate to severe psoriasis with emphasis on the Psoriasis Area and Severity Index (PASI). We’ve just advanced substantial start-up payments to vendors towards the trial, an action that we feel will continue to grow shareholder value.
“I wish to point out that Dr. Bertolino is now introducing Prurisol to large pharmas, most of which are embracing it for the first time. We believe that the path to a large financial deal is generation of comparably encouraging data in Phase 2b as recently seen in our completed Phase 2a trial,” he said.
Interim analysis of top-line phase 2b results of Cellceutix’s study is expected in the second quarter of 2017.
The third candidate in the pipeline is Brilacidin, which has shown antibacterial, anti-biofilm and anti-inflammatory properties in various pre-clinical studies. Currently underway is a phase 2 trial evaluating the oral rinse Brilacidin-OM for the treatment of chemoradiation-induced oral muscositis (OM), an inflammatory condition, in head and neck cancer patients.
“Having data, demonstrating Brilacidin can fight inflammation and doesn’t accumulate in the blood is a major benefit for what can be a painful and expensive condition that doesn’t have any FDA approved treatments. We greatly look forward to additional data from this trial expected in the first half of 2017,” said Ehrlich.
Cellceutix’s pursuit of FDA approval for the products in its pipeline is piquing the interest of larger peers, according to Ehrlich, which in recent months has resulted in more “high-level” business development meetings than at any other time in the company’s history.
“Over the years we have gone from a company with only a single lead drug candidate in an early clinical study to a company that has effectively has three lead drug candidates at mid-state trials targeting multiple indications with new possibilities cropping up regularly underscored by our robust pipeline. We’re having success at targeting multi-billion dollar opportunities with new drugs that can provide relief for millions of people worldwide suffering from hard-to-treat maladies. I believe that is more than ample reason to be excited about all that we have accomplished our future and the litany of catalyst expected in 2017,” said Ehrlich.
For more information, visit the company’s website at www.cellceutix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cellceutix’s lead cancer drug candidate is Kevetrin™, an Orphan Drug anti-cancer agent entering phase 2a clinical trials for the treatment of ovarian cancer. Upon commercialization, Kevetrin would be the world’s first p53-modulating drug. The company is also conducting research to develop an oral formulation of Kevetrin, taking advantage of the drug’s short half-life of roughly two hours.
“If we can develop an oral Kevetrin dosing possibilities are numerous. Perhaps two times or three times a day and seven days a week. Now you know why we are excited. A drug activating p53 and dosed orally, we think would have blockbuster potential. More research needs to be done to validate the clinical effectiveness of Kevetrin as well as developing an oral formulation. But I’d hope investors now understand why we get excited about the possibility of developing both the world’s first safe p53 modulating drug and an oral formulation,” Ehrlich stated in the company’s fiscal Q1 2017 earnings call in September (http://dtn.fm/2l0JR).
Another propellant of progress is an anti-psoriasis drug candidate the company once called a “dark horse” or “long shot.” Advancing through two successful clinical trials, however, the potential of Cellceutix’s Prurisol™, now in phase 2b trials, is starting to take shape.
“We believe that the potential safety profile of Prurisol may make this an attractive alternative to Celgene’s (NYSE: CELG) OTEZLA, which is on its way to achieving $1 billion in sales within just three years of its launch,” Arthur P. Bertolino, MD, PhD, MBA, president and chief medical officer at Cellceutix, stated in a recent news release.
In the previously mentioned September business update, Ehlrich also noted Allergan’s (NYSE: AGN) $639 million acquisition of Vitae Pharmaceuticals’ (NASDAQ: VTAE) two clinical drug candidates, one of which is an oral therapy for psoriasis (http://dtn.fm/JJ3mQ).
“I share this with you because it exemplifies the premium that the industry is placing on new, oral psoriasis drugs, even those in mid-stage development. I’m not in the business of analysis, but it seems to me that Allergan values VTP-43742 at more than our total market capitalization. As such, we see a tremendous market opportunity with Prurisol and greatly look forward to initiating our Phase 2b trial in patients with moderate to severe psoriasis with emphasis on the Psoriasis Area and Severity Index (PASI). We’ve just advanced substantial start-up payments to vendors towards the trial, an action that we feel will continue to grow shareholder value.
“I wish to point out that Dr. Bertolino is now introducing Prurisol to large pharmas, most of which are embracing it for the first time. We believe that the path to a large financial deal is generation of comparably encouraging data in Phase 2b as recently seen in our completed Phase 2a trial,” he said.
Interim analysis of top-line phase 2b results of Cellceutix’s study is expected in the second quarter of 2017.
The third candidate in the pipeline is Brilacidin, which has shown antibacterial, anti-biofilm and anti-inflammatory properties in various pre-clinical studies. Currently underway is a phase 2 trial evaluating the oral rinse Brilacidin-OM for the treatment of chemoradiation-induced oral muscositis (OM), an inflammatory condition, in head and neck cancer patients.
“Having data, demonstrating Brilacidin can fight inflammation and doesn’t accumulate in the blood is a major benefit for what can be a painful and expensive condition that doesn’t have any FDA approved treatments. We greatly look forward to additional data from this trial expected in the first half of 2017,” said Ehrlich.
Cellceutix’s pursuit of FDA approval for the products in its pipeline is piquing the interest of larger peers, according to Ehrlich, which in recent months has resulted in more “high-level” business development meetings than at any other time in the company’s history.
“Over the years we have gone from a company with only a single lead drug candidate in an early clinical study to a company that has effectively has three lead drug candidates at mid-state trials targeting multiple indications with new possibilities cropping up regularly underscored by our robust pipeline. We’re having success at targeting multi-billion dollar opportunities with new drugs that can provide relief for millions of people worldwide suffering from hard-to-treat maladies. I believe that is more than ample reason to be excited about all that we have accomplished our future and the litany of catalyst expected in 2017,” said Ehrlich.
For more information, visit the company’s website at www.cellceutix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Heron Therapeutics (HRTX) Helps Chemo Patients Prevent Vomiting with SUSTOL®
Cancer is the great scourge of our age. This year, 1.7 million Americans will find out they have the disease and some 600,000 will die from it. In total, approximately 40 percent of the population can expect to be diagnosed with cancer during their lifetime. The name “cancer” is derived from the Greek word for crab and may have been bestowed to indicate the tenacity of the disorder. Cancer tends to persist with the same relentlessness as the claws of a crab cling to a victim.
Yet despite its stubbornness, cancer treatments like chemotherapy have reduced fatalities. Cancer is a formidable foe, however, and the fight against it often leads to a Pyrrhic victory. Patients are left seriously debilitated. Now, SUSTOL® (granisetron) from Heron Therapeutics (NASDAQ: HRTX) is available to provide extended relief to chemo patients suffering from Chemotherapy-Induced Nausea and Vomiting (CINV).
About four million people worldwide receive chemotherapy, making it the most common treatment for cancer, but chemo comes with a number of pernicious side effects, one of which is CINV. Cancer patients identified CINV as the side effect of chemo they most wanted to avoid, ahead of depression, constipation, fatigue, diarrhea and sexual dysfunction. The abhorrence to CINV is thought to be the main reason leading to premature discontinuation of remedial chemo regimens.
Chemotherapy agents that give rise to the most intolerable bouts of nausea and vomiting are grouped as either Moderately Emetogenic Chemotherapy (MEC) or Highly Emetogenic Chemotherapy (HEC). About 30-90 percent of patients undergoing MEC treatments and more than 90 percent of those undergoing HEC ones experience vomiting without preventative treatment. Overall, some 70-80 percent of chemo patients experience CINV. These numbers show promising market potential for SUSTOL®.
SUSTOL® was launched in October and is the first and only approved
5-HT3 receptor antagonist offering an extended-release effect and five days of
CINV prevention for MEC and HEC regimens. The 5-HT3 receptor system regulates the body’s emetic (nausea and vomiting) responses. SUSTOL® has two important advantages over the market leader, Aloxi. First, it offers a true extended five-day release, as opposed to Aloxi, which drops off after three to four days, a period considered too short for most MEC and HEC regimens. Second, it has a higher profitability potential for oncologists. Over the past three and a half years, Aloxi has had unit sales in the U.S. of between 600,000-700,000 vials per quarter. Aegis Capital (http://dtn.fm/f2EEv), in a recent report, opines that ‘SUSTOL® represents at least a $300 million opportunity over the next five years’.
There’s more to Heron than SUSTOL®, however. The company’s present pipeline includes HTX-011 and HTX-019. HTX-011 is being tested for post-op pain in nerve block and post-op pain in local administration. HTX-019 is being evaluated for the treatment of CINV.
SUSTOL® and HTX-011 utilize Heron’s proprietary Biochronomer® drug delivery technology, which can deliver therapeutic levels of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection. The Biochronomer® technology consists of bio-erodible polymers, which comprehensive animal and human toxicology studies have established to be safe and well tolerated. When injected into subcutaneous tissue, the polymers undergo controlled hydrolysis, resulting in a controlled, sustained release of the pharmacological agent encapsulated within the Biochronomer-based composition.
Aegis has set a ‘Buy’ rating and a price target of $41.00 on Heron stock, which is currently trading on the NASDAQ under the symbol HRTX at around $15.50.
For more information, please visit www.herontx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Yet despite its stubbornness, cancer treatments like chemotherapy have reduced fatalities. Cancer is a formidable foe, however, and the fight against it often leads to a Pyrrhic victory. Patients are left seriously debilitated. Now, SUSTOL® (granisetron) from Heron Therapeutics (NASDAQ: HRTX) is available to provide extended relief to chemo patients suffering from Chemotherapy-Induced Nausea and Vomiting (CINV).
About four million people worldwide receive chemotherapy, making it the most common treatment for cancer, but chemo comes with a number of pernicious side effects, one of which is CINV. Cancer patients identified CINV as the side effect of chemo they most wanted to avoid, ahead of depression, constipation, fatigue, diarrhea and sexual dysfunction. The abhorrence to CINV is thought to be the main reason leading to premature discontinuation of remedial chemo regimens.
Chemotherapy agents that give rise to the most intolerable bouts of nausea and vomiting are grouped as either Moderately Emetogenic Chemotherapy (MEC) or Highly Emetogenic Chemotherapy (HEC). About 30-90 percent of patients undergoing MEC treatments and more than 90 percent of those undergoing HEC ones experience vomiting without preventative treatment. Overall, some 70-80 percent of chemo patients experience CINV. These numbers show promising market potential for SUSTOL®.
SUSTOL® was launched in October and is the first and only approved
5-HT3 receptor antagonist offering an extended-release effect and five days of
CINV prevention for MEC and HEC regimens. The 5-HT3 receptor system regulates the body’s emetic (nausea and vomiting) responses. SUSTOL® has two important advantages over the market leader, Aloxi. First, it offers a true extended five-day release, as opposed to Aloxi, which drops off after three to four days, a period considered too short for most MEC and HEC regimens. Second, it has a higher profitability potential for oncologists. Over the past three and a half years, Aloxi has had unit sales in the U.S. of between 600,000-700,000 vials per quarter. Aegis Capital (http://dtn.fm/f2EEv), in a recent report, opines that ‘SUSTOL® represents at least a $300 million opportunity over the next five years’.
There’s more to Heron than SUSTOL®, however. The company’s present pipeline includes HTX-011 and HTX-019. HTX-011 is being tested for post-op pain in nerve block and post-op pain in local administration. HTX-019 is being evaluated for the treatment of CINV.
SUSTOL® and HTX-011 utilize Heron’s proprietary Biochronomer® drug delivery technology, which can deliver therapeutic levels of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection. The Biochronomer® technology consists of bio-erodible polymers, which comprehensive animal and human toxicology studies have established to be safe and well tolerated. When injected into subcutaneous tissue, the polymers undergo controlled hydrolysis, resulting in a controlled, sustained release of the pharmacological agent encapsulated within the Biochronomer-based composition.
Aegis has set a ‘Buy’ rating and a price target of $41.00 on Heron stock, which is currently trading on the NASDAQ under the symbol HRTX at around $15.50.
For more information, please visit www.herontx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)